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A UC Area Under Curve 
Cmax Peak plasma concentration 
C/R Renal clearance 
Ch Total body clearance 
CSF Cerebrospinal fluid 
HPLC High Performance Liquid Chromatography 
i.v. Intravenous 
M.A. Microbiological assay 
MBC Minimum bactericidal concentrations 
MIC Minimum inhibitory concentrations 
tn2,xi Distribution half-life 
tn2,xz Elimination half-life 
r„,ax Time of maximum concentration reached 
TCM Tradition Chinese Medicine 
Vd Volume of distribution 
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It has been well documented that the presence of metal cations reduces the 
bioavailability of quinolone antibiotics. Furthermore, the antibacterial effect of this 
class ofantibiotic can also be greatly reduced by the presence of metal cations in vitro. 
Thus far, it is not known how these two observations relate to each other particularly in 
the in vivo situation. In this study, the effects of oral administration of ferrous sulfate 
(lOOmg/kg) on the pharmacokinetics and pharmacodynamics of a single intravenous 
(5mg/kg) and a single oral (20mg/kg) dose of ciprofloxacin were evaluated using a rat 
model. Similarly, the effects ofselected Traditional Chinese Medicines (TCM) having a 
high content mineral on the absorption of ciprofloxacin were examined. Ferrous sulfate 
coadministration with ciprofloxacin given intravenously significantly increased the area 
under the curve {AUQ ofciprofloxacin by 88% {p <0.005) with the terminal half-life 
{ty2x2) prolonged by 4-fold. Similarly, ferrous sulfate tended to reduce the total body 
V 
'' clearance (C/x) and renal clearance ( (¾) of ciprofloxacin by 51% and 47%， 
respectively. Oral administration of ferrous sulfate 75 min after the oral ciprofloxacin 
dose did not significantly affect absorption. On the other hand, a reduction in t h e ^ f / C 
and peak ciprofloxacin concentrations (C..ax) by 73% {p <0.005) and 92% {p <0.005), 
respectively, was observed when ferrous sulfate was administered 2 h before oral 
ciprofloxacin dosing. Under various interaction regimens, the AUC and the urinary 
drug recovery estimated using data generated by microbiological assay (M.A.) were 
lowered by 9 -51% and 35 - 47%, respectively，when compared to those generated by 
vi 
HPLC assay. Therefore, we do not recommend ciprofloxacin to be dosed 
concomitantly with ferrous sulfate even when they are spaced with an adequate time 
interval. 
Four species ofTCMs, i.e. Sangnisorha officinalis L. (SO), Foeniculum vulgare 
Mill. (FV), Taraxacum mongolicnm Hand. Mazz. (TM) and Cinnabaris were tested. As 
with the TCM rich in mineral cations, the reduction mAUC of ciprofloxacin was most 
prominent when the antibiotic was coadministered with SO, while Cinnabaris produced 
least effect on ciprofloxacin absorption. The AUC of ciprofloxacin was reduced by 
78% (p < 0.005) and its G ^ b y 94% {[) < 0.005) by concomitant ingestion of SO. 
However, the corresponding reduction in these two parameters were 48% (p < 0.05) 
and 82% ip < 0.005), respectively for FV. Concomitant ingestion ofTM only reduced 
the Cnux of ciprofloxacin by 44% {p < 0.05) but showed no statistical difference in 
AUC. As shown by the present data, Cinnabaris did not alter the absorption of 
ciprofloxacin. Interestingly, U/2,x2 of ciprofloxacin was prolonged for each TCM tested. 
Therefore, coadministration of SO, FV and TM with ciprofloxacin are not 
* 
recommended because they impair the adsorption of ciprofloxacin and thus reduce the 
bioavailability of the antibiotic. 
Studies in this thesis demonstrate the existence of an interaction of ciprofloxacin 
between ferrous sulfate and TCMs containing a high mineral content. However, the 
impact of such an interaction is not restricted to a'change in the pharmacokinetics of 
ciprofloxacin. In fact, the data collected for the ferrous sulfate and ciprofloxacin 
interaction study demonstrate a significant reduction in the antibacterial effect of the 
vii 
antibiotic in vivo. This pharmacokinetics and pharmacodynamics observed in the 
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1.1 Characteristics of quinolones 
During the last two decades, quinolone antibiotics with the 1, 4 - dihydro - 4 -
0X0 - 3 - quinolinecarboxylic acid skeleton that show a considerable degree of 
antibacterial activity have been developed. The use of the first-generation quinolone 
antibiotics, such as nalidixic acid and oxolinic acid，has been restricted for the 
treatment of urinary tract infections because of their low concentrations in serum, 
short biological half-lives, and the rapid development of resistance. In addition, the 
spectra of antimicrobial activity for these earlier quinolones are rather limited. The 
V 
' second-generation quinolones carry a fluorine atom in the sixth position and bear a 
piperazinyl moiety in the seventh position. It seems that both substituents are 
required for the improvement of activity against a broad spectrum of microorganism 
(Muytjens H.L. et al., 1983) as well as intestinal drug absorption. 
The introduction of the new fluoroquinolones for clinical use some 15 years 
ago has raised great expectation. The fluoroquinolones are considered to be an 
"ideal" antimicrobial agent since they possess a broad antibacterial spectrum for both 
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Gram-positive and Gram-negative bacteria and other organisms, induce a low 
frequency of spontaneous single-step mutations, and exhibit excellent oral absorption 
and good tissue distribution. They also provide adequate penetration into 
macrophages and other phagocytic cells and show excellent urinary concentrations 
because of their relatively high degree of renal excretion. 
Ciprofloxacin (1 - cyclopropyl - 6 - fluoro - 1, 4 _ dihydro - 4 - oxo - 7 _ ( 1 -
piperazinyl) - 3 - quinolinecarboxylic acid) (Figure 1.1) is one of the second-
generation of fluoroquinolones, and has been widely used in clinical situations. It is 
currently available in the form of a pale and yellow crystalline hydrochloride salt, and 
has a molecular weight of 385.8. It is slightly photosensitive after prolonged 
exposure, therefore, the drug should be protected from strong ultraviolet light. 
Because of its relatively higher activity than other fluoroquinolones (van 
Caekenberghe D.L. et al., 1984; Goodman LJ. et al., 1984 and Eliopoulos G.M. et 
*• 
al., 1984), it should be used as an alternative for the treatment of problematic 
infections especially against Pseudonionas aeruginosa. 
1.2 Pharmacokinetics of ciprofloxacin in human 
The pharmacokinetics of antibacterial agents usually involve description of 
the processes of absorption, distribution, metabolism and elimination (ADME). 
Because these four processes not only characterize the pharmacokinetics of an 
2 
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antibacterial agent, they also influence significantly on the antibacterial efficacy of the 
agent against infections at various sites. A general understanding of these processes 
will permit a better description of the agents' antimicrobial activity. The following 
information provide a brief overview of the pharmacokinetic behaviour of 
ciprofloxacin. 
1.2.1 Absorption 
Ciprofloxacin is absorbed along the gastrointestinal tract. Drug absorption 
after oral administration of ciprofloxacin in the form of tablet is rapid from the 
gastrointestinal tract with good absolute bioavailability at about 64-85% in human 
^Iofflcen G. et a/.,1985 and Drusano G.L. et a/.,1986). Furthermore, the extent of 
absorption decreases from nearly 100% in the duodenum and jejunum to 25% in the 
ileum and less than 5% in the descending colon. Therefore, the upper part of the 
V-
^ intestinal tract, i.e., the duodenum and jejunum should be considered as the main 
absorption site for ciprofloxacin (Staib A.H. et al., 1989). 
1.2.2 Distribution 
The volume of distribution of ciprofloxacin is large. Its apparent steady-state 
volume distribution is approximately 2 L/kg which is 2-3 times of total body water 
(Gonzalez M.A. et al., 1985). The plasma protein binding of ciprofloxacin is low (20-
3 
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40%) as ciprofloxacin is small in molecular size and is a zwitterion (Lebel M., 1988). 
After oral or intravenous administration, ciprofloxacin is widely distributed 
throughout body fluids and tissues. Tissue concentrations in human often exceed 
serum concentrations, particularly in genital tissue including the prostate. 
Ciprofloxacin distributes into the sputum, pleural fluid and muscle while 
concentrations in these organs are similar to that of the serum. Concentrations of 
ciprofloxacin are higher than serum in epithelial cells, macrophages, polymorphs, 
gastric mucosa, bile and the lung. The drug also difRises across the blood brain 
barrier into the cerebrospinal fluid (CSF); however, the degree of penetration is less 
than 10% when peak serum and peak CSF concentrations are compared (Valainis G 




* After oral administration of "C ciprofloxacin，it has been observed that 19% 
ofthe dose is excreted as metabolites in both urine and feces (LeBel M.，1988). Four 
ciprofloxacin metabolites (Ml, M2, M3 and M4) have been detected in urine and 
feces; these are the ethylene diamino- (Ml), sulfonyl- (M2), oxo- (M3), and 
formamido- (M4) metabolites (Figure 1.2) (Krol G.J. et al., 1986). The antibacterial 
activity of the metabolite Ml is comparable to that of nalidixic acid, whereas M2 is 




negative bacteria and is similar to ciprofloxacin against Staphylococci. M3 shows a 
broad spectrum ofantibacterial activity which is slightly less than that ofnorfloxacin. 
The fecal and urinary recoveries ofMl，M2 and M3 metabolites accounted 
for 18.8% (7.5% in feces and 11.3% in urine) following a oral ^^-labeled 
ciprofloxacin dose. In fact, M2 (9.6%) and M3 (7.3%) make up the major portion of 
this total recovery. On the other hand, only a small amount (1.8% of the dose) was 
excreted as Ml. Another metabolite, M4 has also been detected in very small 
quantities (0.1% of the dose). The amount o f M 2 has been shown to decrease by 
about one-halfwhen ciprofloxacin was administered intravenously, suggesting that it 
is a product of first-pass metabolism after oral administration (Wingender W. et al., 
1984). Despite the presence of these metabolites, previous reports have indicated no 
significant differences in serum ciprofloxacin concentrations measured by both HPLC 
and microbiological assays (M.A.) (Jehl F. et a/., 1985 and Morton S.J. et al., 1986). 
1» 
This observation suggests that contribution of ciprofloxacin of its antimicrobial 
activity by these metabolites is negligible. 
1.2.4 Elimination 
Ciprofloxacin undergoes a small degree of.first-pass effect and is eliminated 
predominantly by renal and biliary routes (Lebel M., 1988). Most, if not all, 
fluoroquinolones undergo glomerular filtration and active secretion by the proximal 
5 
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tubules in the form as either anions or cations (Sorgel F. and Kinzig M.，1993). The 
anionic secretion mechanism has been proven for ciprofloxacin by its blockage using 
probenecid, while the cationic transport system may be inhibited by cimetidine. The 
renal clearance of ciprofloxacin ranges from 335-479 ml minute'^ (Wise R. et al., 
1984 and Hoffken G. et a/.,1985) and exceeds normal glomerular filtration rate of 
120 ml minute] This indeed helps to prove the significant role of active tubular 
secretion in its elimination. About 29.5% and 57% of the unchanged ciprofloxacin 
could be recovered in the 24 h urine after oral and intravenous dosing, respectively 
(Hoffken G. et al., 1985). In cases when renal function is normal, urinary excretion 
ofciprofloxacin should virtually be completed within 24 h after dosing. 
1.2.5 Pharmacokinetics of ciprofloxacin in the rats 
The use of animal models in pharmacokinetic studies may have implications 
V" _ 
^ on data interpretation because of the differences in pharmacokinetics of a drug 
between animals and men. It has been well documented that animals eliminate drugs 
faster than men (Dedrick R.L., 1973). 
Following oral administration of "C ciprofloxacin to the rat, the absolute 
bioavailability of ciprofloxacin has been found to be only 30-40% (al-Klamis K.I. et 
al, 1994). This is lower than that of human which is about 80%. Plasma 
concentration of unchanged ciprofloxacin peaks at 0.33 h (Siefert H.M. et a/.，1986) 
6 
Chapter 3 
and is much shorter than that of humans (1 to 1.5 h) O^ix D.E. et al., 1988). The 
elimination half-life of unchanged drug in the rat，ranges from 1 to 2 h (al-Klamis K.I. 
et al., 1994)，and is also shorter than that observed in humans (range 3 to 4.4 h) 
(WiseR. etal., 1984 and Lettieri J.T. etal., 1992). The absorption and disposition of 
ciprofloxacin will be discussed in more detail in subsequent chapters. 
1.3 Pharmacodynamics 
Pharmacodynamics can be defined as the quantitative relationship between 
plasma and/or tissue concentrations of the active moiety and the magnitude of the 
pharmacological effect(s) observed. Pharmacodynamics of antibiotics concem 
primarily the relationship between drug concentration and antimicrobial effect. 
Traditionally, the minimum inhibitory and bactericidal concentrations (MIC and 
MBC) have been major parameters used to characterize the degree of antimicrobial 
Y 
‘ effect anticipated in vivo. However, in some cases, MIC values do not necessarily 
reflect the exact therapeutic value of an antibiotic. This is due to the fact that MIC 
values do not consider the pharmacokinetics of the antibiotics and give no indication 
of the bactericidal activity and postantibiotic effect exhibited by the antibiotics. 
Furthermore, in vivo antibacterial activity achievable in body tissues and fluids is 
mostly dependent on the pharmacokinetic properties of a particular antibiotic. In 
general, MIC of ciprofloxacin against fully susceptible organisms ranges from 0.008 
7 
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to 1.0 ^ig/ml of which this range of concentrations can be readily achieved in vivo 
(Lettier J.T. etal., 1992). 
1.4 Structure-activity relationship of ciprofloxacin 
Ciprofloxacin is one of the second generation quinolones. The quinolones 
similar to the sulfonamides and nitrofurans are totally synthetic compound. They are 
derived by substitution of 1’ 4 - dihydro - 4 - oxo - quinolone - 3 - carboxylic acid at 
the nitrogen atom of position 1. The second generation quinolones possess a broad 
spectrum of antibacterial activity because of the replacement of the hydrogen by a 
fluorine at position 6 and the new cyclopropyl moiety at position 1 of the quinolone 
ring (Figure 1.3) such that the antibacterial efficacy has been markedly enhanced. 
1-position: A prerequisite for the potent antibacterial activity of quinolones is the N-
V 
atom in the first position. Significant increase in activity has been 
achieved by radicals such as a cyclopropyl group which cause more steric 
hindrance. This cyclopropyl group attached to the quinolone ring is 
related to increase in its activity against Mycoplasma and Chlamydia. 
3-position: The formation of hydrogen bridges between the carboxyl group at the 3-
position and the adjacent 4-oxo grOup. This is regarded as being 




4-position: Substitutions at the 4-position have been investigated to a lesser extent 
because the presence of the 4-oxo group is regarded as necessary for the 
inhibition ofDNA gyrase. 
6-position: Newer quinolones carry a fluorine atom at the 6-position 
(fluoroquinolones). Fluorination is proven to have advantages over other 
C-6 substituents. With this, the inhibition of DNA gyrase and ability to 
penetrate through cell membrane are improved dramatically. From a 
pharmacokinetic point of view, intestinal absorption is also enhanced by 
the introduction of a fluorine atom. Furthermore, the fluorine atom 
enhances the activity of the molecule against Gram-positive pathogens. 
7-position: Variations at the 7-position have been most extensively studied. 
Substitutions at the 7-position affect both the activity and the 
pharmacokinetics properties of the compound. Cyclic amines are the 
most common substituents at the 7-position with which further ring 
、 
systems can be fused or linked spirocyclically. The piperazine group at 







The mode of action of ciprofloxacin relates directly to the inhibition of its 
intracellular target, DNA gyrase. DNA gyrase is a member of the family of enzymes 
known to be DNA topoisomerases. There are two types of DNA topoisomerases, 
i.e., I and II，which are characterized by the reactions involving the breaking of 
single- or double-stranded DNA, respectively. DNA gyrase is a type II enzyme and is 
composed o f 4 subunits, i.e., 2 alpha (a) and 2 beta (p) subunits. The active DNA 
gyrase carries the configuration of a2P2 of which the alpha subunits are the primary 
target for ciprofloxacin. The bactericidal potency of individual fluoroquinolones is 
closely related with their inherent abilities to bind to and to inhibit the activity of 
DNA gyrase. Ciprofloxacin has the most potent DNA gyrase-inhibiting activity ofthe 
fluoroquinolones currently available. In addition, the degree of DNA-gyrase 
inhibition seems to correlate with the MIC. The gyrase is essential for the normal 
•» 
physiology of the bacteria as it is involved in a number of cellular processes including 
DNA replication, transcription, repair and recombination. However, it is apparently 





The use of nalidixic acid in the treatment of severe infections has been limited 
as a result of rapid development of bacterial resistance. Fluoroquinolones appear not 
to be sensitive to plasmid- or enzyme-mediated resistance. Bacteria become resistant 
to these agents by spontaneous single-step chromosomal mutation associated with 
alternation in the alpha subunit. 
1.7 Clinical uses of ciprofloxacin 
The quinolones continue to make a significant contribution to the fight against 
community- and hospital-acquired infections and to add a new dimension to the well-
established armamentarium of anti-infective drugs. Extensive clinical experience 
especially with ciprofloxacin and also with norfloxacin and ofloxacin together with a 
V 
. rich body of post-marketing data have confirmed the high tolerability and efficacy of 
these quinolones. 
From the prospective of antimicrobiol activity, lower MIC of ciprofloxacin 
have been observed for the members of the family Enterohacteriacea (including ^-
lactamase-producing strains). A slightly higher MIC against Pseudomonas 
aeruginosa with MIC90 in the order of 0.5 ^ig/ml (including strains resistant to 
gentamicin or carbenicillin) has also been reported (Weber A. H. et al ,1985). 
11 
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Ciprofloxacin is potentially useful for the treatment of systemic infections and it does 
not induce cross-resistance against other antimicrobial agents such as beta-lactams or 
aminoglycosides. 
In clinical trials, oral and intravenous ciprofloxacin administration yielded 
similar clinical and bacteriologic results compared to other standard therapy such as 
aminoglycosides and p-lactam (Paladino J.A. et al., 1991). It is a useful alternative to 
aminoglycosides and P-lactam antibiotics against a wide array of systemic infections 
including lower and upper urinary tract infection, gonococcal urethritis, and 
infections involving skin, skin structure, bone, respiratory tract and gastrointestinal 
tract (Wise R. et al., 1983 and Grasela T.H. et “/., 1991). 
1.8 Drug interactions 
V 
V 
A number of well-known drug interactions have been reported between 
various drugs and ciprofloxacin; for example, fenbufen-ciprofloxacin O^aora K. et al., 
1990), famotidine-ciprofloxacin (al-Khamis K.I. et a/., 1994), antacids-ciprofloxacin 
(Frost R.W. et al,, 1992) and etc. These interactions mainly are results of altered 




1.8.1 Interactions during the absorption process 
Ciprofloxacin is one of the fluoroquinolones that shows good absorption 
along the gastrointestinal tract. It is primarily absorbed in the duodenum and jejunum. 
Administration of ciprofloxacin with food does not reduce the amount of drug 
absorbed, but changes the rate of absorption. The food effect results in reduction of 
the maximal drug concentrations in plasma (Cnax) and a prolongation of the time 
required to reach such maximal concentration (7;,ax)- With food, Cmax decreases by 
17-20% and Z;,ax increases from 0.2 tol.2 h (Ledergerber B. et al., 1985). 
Ciprofloxacin can form metal chelates via the 3-carboxyl and 4-oxo functional 
groups with various polyvalent cations such as AP+，Mg�+ and Ca?+ (Nix D.E. et al., 
1989b and Frost R.W. et a/.’ 1992). These cations can usually be found in antacids 
used for gastric distress. It is believed that these complexes cannot be absorbed by 
V 
the gastrointestinal tract and leads a reduction in the oral bioavailability of 
ciprofloxacin. Besides AT?+，Mg�+ and Ca�+, other cations such as Fe�+ and Zn?+ can 
also form chelates with ciprofloxacin and reduce its bioavailability (Polk P.E. et al., 




1.8.2 Interactions due to alterations in metabolism 
Ciprofloxacin inhibits hepatic enzymes but does not cause any changes in 
hepatic blood flow. Due to the inhibition of hepatic metabolic enzymes, concurrent 
administration of ciprofloxacin and theophylline can cause an undesirable rise in the 
serum theophylline concentrations which in turn can lead to side effects due to over 
exposure to theophylline. (Wijnands W.J. et al., 1986 and Nix D.E. et al., 1987b). 
Caffeine clearance was also reduced approximately by 33% when given after a 5-day 
pretreatment with ciprofloxacin (Staib A.H. et al.�1987). Similar to theophylline, 
hepatic enzyme inhibition by ciprofloxacin is behind this reduction in clearance. 
1.8.3 Alterations in renal excretions 
About 20-40% of unchanged ciprofloxacin is excreted in the urine after oral 
V 
dosing. Renal ciprofloxacin excretion is not only by means of glomerular filtration 
and also by tubular secretion. Renal clearance for ciprofloxacin reduced from 4.6 ml 
min'i kg-i to 2.3 ml min'^  kg"^  when 1 g of probenecid was given orally prior to the 
administration of 500 mg of ciprofloxacin. As probenecid is an inhibitor of active 
tubular secretion and its high affinity for anion carrier (Sorgel F. and Kinzig M.， 
1993)，it is therefore expected that drug completing for tubular secretion may interact 
with ciprofloxacin. The half-life of ciprofloxacin is prolonged by some nonsteroidal 
anti-inflammatory drugs such as fenbufen and total clearance of ciprofloxacin can be 
14 
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reduced by as much as 20% QSfaora K. et al., 1990). In fact, the reduction in the renal 
clearance of ciprofloxacin by the coadministration of fenbufen may be due to 
competitive inhibition for renal tubular secretion via the anion transport mechanism. 
As with this interaction, elevation in plasma concentration of ciprofloxacin may lead 
to neurotoxic side effects such as seizures. 
1.9 The interactions between ciprofloxacin and metal cations 
Ciprofloxacin is a widely used antimicrobial agent because it provides more 
cost-effective treatment against various infections. A potential problem with the 
increasing use of ciprofloxacin for the treatment of systemic illness，especially when it 
is given orally, is the interaction with metal cations as a result of chelate formation. 
Many previous studies have demonstrated a variety of medications containing 
V 
- metal cations that can interfere with ciprofloxacin bioavailability in human; the 
absorption of orally administered ciprofloxacin is decreased by concomitant 
administration of antacids which contain aluminum, magnesium and calcium. It has 
\ 
been shown that when ciprofloxacin is given with aluminum hydroxide and calcium 
carbonate, the relative bioavailability can be reduced approximately by 85% and by 
40%, respectively (Frost R.W. et al., 1992). Therefore, it is recommended that 
antacid should be administered 6 h before or 2 h after oral ciprofloxacin dosing to 
reduce the extent of such an interaction (Nix D.E.,1989b). Mineral supplements such 
15 
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as Fe2+ and Zr?^ also interact with ciprofloxacin (Polk R.E. et al., 1989); by 
concomitant ingestion of ferrous sulfate, the A lJC and peak plasma concentration of 
ciprofloxacin have been found to be reduced by 57% and 54%, respectively (Lehto P. 
et al., 1994). Iron supplements available in the form of ferrous salts are among the 
most commonly prescribed drugs and are taken by many people as over-the-counter 
medications. Among various salt forms, ferrous sulfate is most commonly used 
because divalent iron shows relatively higher bioavailability and it is up to 16 times 
better absorbed than trivalent iron. Besides, it produces a better response than other 
preparations (Dietzefelbinger H.，1987). Nevertheless，ferrous sulfate has been shown 
to interfere with the bioavailability of a number of drugs, including thyroxine, 
tetracycline and its derivatives，penicillamine, methyldopa，levodopa, carbidopa， 
ciprofloxacin and the newer fluoroquinolones. In vitro, AP+ and Fe;+ have been 
shown to possess, among other cations, the strongest chelation potential with 
quinolones. Furthermore, the order of stability constants among divalent metal 
cations is Cu?+ >Fe^^ >Zn^^ >Mg^" >Ca^^ (Yukinori K. et al., 1996). The site of 
metal chelation is believed to be the 3-carboxyl and 4-oxo groups of the quinolone 
ring (Figure 1.4). An increase in the MIC of ciprofloxacin has been noticed in the \ 
presence of metal cations and this decrease in antimicrobial activity corresponds with 
the cation concentrations (Li R.C. et al” 1994). For two bacterial species, i.e., 
• 
Escherichia coli ATCC 25922 and Pseudomonas aerugwosa ATCC 27853, the 
order of cation induced antagonism demonstrate in vitro by the six cations Al�+ >Pe^^ 
>Mn2+ >Zn2+ >Mg2+ >Ca^^ (Li R.C. et “/.’ 1994).‘ 
16 
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1.10 Traditional Chinese Medicines 
The use of Traditional Chinese Medicines (TCM) is common in Asia and that 
its use has been documented for thousands of years. As with the increasing use of 
health foods and diet supplements obtained from herbal sources, TCM now plays an 
important role in the health care system in the world. In China, many people use 
TCM as an alternative medical treatment or supplementation for western 
pharmacotherapy, especially for chronic diseases. 
The principles of TCM use are entirely different from that of modem 
medicine originated in the Western world. As it is common in most cases that the 
active ingredients in TCM cannot be identified, the use of both western drug and 
TCM causes a great concern for potential drug-drug interactions. From this 
prospective, a number of herbs are known to contain a large amount of minerals. 
V 
‘ Therefore, cation-ciprofloxacin interactions in theory can take place with TCM 
provided that the content of metal cations in these herbs is significantly high. 
\ 
1.11 Plans ofthe study 
Knowing that presence of metal cations reduces the antimicrobial activity of 
ciprofloxacin, there is a distinct possibility that the bioavailability of ciprofloxacin 
may not be an adequate indicator for the drug in viyo activity. This is especially so if 
17 
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metal cations are also present in the blood stream even when the dosing time of the 
metal cations has been spread over a longer interval. Previous studies have only 
shown a reduction in oral bioavailability for ciprofloxacin when the antibiotic is 
concomitantly administered with agents containing metal cations. Because of reduced 
gastrointestinal absorption as a result of complexes formation, it is recommended that 
antacid should be dosed six hours before or two hours after oral ciprofloxacin. 
However, such recommendation appears not to be applicable to intravenous 
ciprofloxacin dosing as no physical contact of the two moieties will take place in the 
gastrointestinal tract. The objectives of this thesis are to investigate the possibility of 
an interaction both inside and outside the gastrointestinal tract (particularly when 
both agents exist in blood) and the influence of selected TCM on the 







F ^ ^ ^ / ^ \ ^ C � � 
^ N ^ " ^ ^ ^ N ) 
0 入 





F ^ Y ^ x ^ ^ J k ^ C O O H 
^ N ^ ^ ^ N ^ 
/ 心 k \ 
於 Ciprofloxacin ^ V o 
F ^ ^ ^ c o o H ' Y T Y ' " 
r ^ N ^ V r ? ^ V 
I 人 OHC-N\ J A 
H03s-N^ A ^ ^ 
Sulfociprofloxacin (M2) 0 Formylciprofloxacin (M4) 
F ^ ^ ^ \ / ^ C O O H 
/ ^ M ^ ^ ^ ^ ^ ^ X f S i � 
I 1 II i 







F ^ Y ^ ^ \ ^ A ^ C O O H 
/ " ^ y v � � 
"^ ^ M 'i 入 
DesethylenecipPofloxacin (Ml) 
Figure 1.2 Structure formulas of ciprofloxacin and its metabolites. 




• = ~ \ y ^ ^ � \ ^ -












/ � \ 
0 0 
� F ^ " " ^ ^ r " ^ " > ^ c 
^ N ^ ^ ^ ^ � � 
• 
H N ^ ^ ^ A 
\ 
Figure 1.4 The proposed molecular structure for the 




Assay Development for Ciprofloxacin 
2.1 Introduction 
Several methods are available for the quantification of ciprofloxacin. They 
include a microbiological assays (M.A.) (Bennett J.V. et al., 1966; Crump B. et al., 
1983 and Joo B. et al., 1985) and high performance liquid chromatography (HPLC) 
assays Q^ix D.E. et al.’ 1985; Weber A. et al., 1985; Krol G.J. et al., 1986 and 
Nilsson-Ehle I.，1987). The HPLC method is highly specific and sensitive, and is 
preferable to more time-consuming and less specific microbiological method because 
active metabolites may magnify the effect of the drug in M.A.. Nevertheless, both the 
•, 
V 
. M.A. and HPLC assays are used to quantitate the concentrations of ciprofloxacin in 
plasma and urine in the present studies. As the HPLC assay only measures the 
quantity of ciprofloxacin in the systemic circulation, its antimicrobial activity cannot 
be ensured by this assay particularly if cations are also available in the circulation. 
Therefore, the M.A. was used to measure ciprofloxacin antimicrobial activity. 
9 
A variety of HPLC methods has been reported for the analysis of 
ciprofloxacin in biological fluids. (Joo B. et al., 1985; Nilsson-Ehle I.，1987 and Jim 
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L.K. etal., 1992). In the present study, the concentrations of ciprofloxacin in plasma 
and urine were measured by HPLC, using a modified method of Nix D.E. et al. 
(1985). The mobile phase was changed to consist of 1% (v/v) methanol, 13% (v/v) 
acetonitrile and 86% (v/v) phosphate buffer with a few amount of triethylamine and 
acetic acid. 
It also has a variety of microbiological methods to quantitate 
microbiologically active drug in biofluids (Crump B. et al., 1983; Brittain D.C. et al., 
1985; Jehl F. et al., 1985; Joos B. et al., 1985 and Wise R. et al., 1984). It is more 
common to use an agar diffusion assay (Brittain D.C. et al., 1985 and Joos B. et al., 
1985) to quantitate the concentration of antibiotic. In the present study, Escherichia 
coli ATCC 25922 (Difco laboratories, U.S.A.) was used as test stain which was 
sensitive to ciprofloxacin (Li R.C. et al” 1994). 
V 
2.2 HPLC assay 
\ High-performance liquid chromatography (HPLC) is a rapid, precise and 
reliable analytical tool for the quantitation of many drugs and is vital for clinical trials 





HPLC is also the analytical method of choice for measuring ciprofloxacin. 
Most recent methods involving the use of a reversed-phase column show good 
resolution, short analysis running time and high sensitivity. Therefore, ciprofloxacin 
concentrations in blood and urine collected in the following studies were quantified 
using a reversed-phase HPLC system. A Spherisorb octadecylsilane (ODS) column 
(4.6 mm i.d. x 250 mm, 5 i^m particles; Alltech, Inc., Bellefonte, Pa.) fitted with a 
guard column was used for separation. The Hewelett Packard series 1050 consisting 
of a pump system, an autosampler and an UV detector was used. The mobile phase 
consisted of 0.1 M sodium dihydrogen phosphate monohydrate containing 1% (v/v) 
HPLC grade glacial acetic acid and 0.5% (v/v) triethylamine adjusted to pH 3.0, 
acetonitrile and methanol (83:16:1, v/v). It was degassed daily after filtering through 
a 0.45-fam nylon membrane filter. The flow rate of the mobile phase was set at 1.1 
mVmin and the effluent was monitored by an UV detector at 278 nm. 
v 
V 
Plasma protein precipitation was accomplished by the addition of 200 i^l 
acetonitrile containing 100 ng enoxacin as internal standard to an aliquot of 100 t^l of 
plasma sample in a disposable polypropylene microcentrifuge tube (1.8 ml). After 
mixing for 20 s on a vortex mixer, the mixture was then centrifuged at 10,000g for 5 
min immediately. A volume of 200 pil of clear supernatant was transferred to a clean 
r 





Concentrator (Labconco, U.S.A.) at 35°C. The residue was reconstituted by the 
addition of70 ^1 of mobile phase, and a 50 i^l aliquot was injected into the HPLC. 
The urine samples were diluted with deionized distilled water containing 10 
^il/ml internal standard. The dilution factor was 1:50 for samples collected over the 0-
2，2-4，4-6 h intervals and 1:10 for the sample collected over the 6-24 h intervals. 
After mixing, the diluted urine samples were then centrifuged at 10,000g for 5 min. A 
volume of 50 p.1 of the clear supernatant was injected onto HPLC. 
The peak of the internal standard (enoxacin) and ciprofloxacin appeared to be 
well resolved with retention times at 7.0 and 9.0 min, respectively (Figure 2.1). No 
interfering peaks from endogenous materials were detected in the chromatograms of 
blank plasma (Figure 2.2) and urine (Figure 2.3). The limit of detection were 0.025 
Hg/ml for both of plasma and urine. The actual concentrations in the sample were 
* 
calculated from the calibration curves constructed by plotting peak-areas ratio of 
ciprofloxacin to internal standard against the known concentrations of ciprofloxacin 
§tandards in plasma and urine. 
2.2.1 Linearity 
r 
The quantitation of ciprofloxacin concentration was performed using peak-
area ratio of ciprofloxacin to the internal standard:To determine linearity, 100 ^ig/ml 
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stock solution was serially diluted with blank plasma obtained from the rat and a 
range ofconcentrations at 0.05, 0.10, 0.40, 0.80, 1.50，3.00 pigAnl was obtained. The 
peak-area ratios versus concentrations were linear over this range. The same 
procedure was followed for the urine, except a higher concentration range from 1.0, 
2.0，4.0，8.0，10.0 pig/ml was employed. Satisfactory linearity was also observed in 
the range 1.0-10.0 ^ig/ml for ciprofloxacin in urine as suggested by the linear 
regression analyses. The regression equations describing of the calibration curves 
were y=O.OOlx - 0.0325; r =0.9998 for plasma (Figure 2.4) and y=0.0001x - 0.007; r 
=0.9995 for urine (Figure 2.5). The excellent correlation coefficients observed 
support good linearity of the assays. 
2.2.2 Sensitivity 
The limit of quantitation for this method pertaining to both the plasma and 
•*• 
urine assays were 0.025 p-g/ml for ciprofloxacin. 
2.2.3 Precision \ 
Five replicates of the quality control samples at 0.10, 0.80, 3.00 ^ig/ml (low, 
medium, and high quality control samples) were assayed on the same day. A portion 
of these quality control samples was assayed on different days for which the 
percentage deviation, and the coefficient of variation were calculated. 
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The intraday precision (random analytical variation) as assessed by 5 replicate 
analyses at the three different ciprofloxacin concentrations showed a low coefficient 
of variation of 1.4 - 2.9%. The interday precision (total analytical variation) as 
assessed by assaying these same concentrations 6 times over a 4 week period showed 
the interday coefficients of variation from 2.9 to 9.3%. 
2.2.4 Recovery 
The absolute recovery of ciprofloxacin from plasma was evaluated by 
comparing the peak areas for samples following protein precipitation by acetonitrile 
with the peak areas obtained from aqueous solution at the same concentrations. A 
known amount of ciprofloxacin was diluted with antibiotic-free plasma and assayed at 
three different concentrations i.e., 0.10’ 0.80, 3.00 ^ig/ml. The concentrations 
measured following the addition of acetonitrile were compared to those of the 
V 
aqueous standards. As shown in Table 2.1 the respective mean recoveries of 
ciprofloxacin at the those concentrations were 62.1, 76.3, 75.1%, respectively. 
\ 
2.2.5 Stability 
Stability studies of ciprofloxacin in plasma .were performed over a 4 month 
period. Plasma samples were spiked with ciprofloxacin to yield a range from 0.05 to 
3.00 i^gAnl. Pooled plasma samples were divided into 100 i^l batches and stored in a 
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freezer at -80°C until the time of analysis. The results demonstrated that 
ciprofloxacin can be stored frozen in serum for at least 4 month without degradation 
(Table 2.2). 
To contrast the ciprofloxacin concentrations obtained by the HPLC assay to 
that of the microbiological assay (M.A.) in an attempt to discern the relationship 
between ciprofloxacin concentrations and antimicrobial activity observed, a M.A. was 
developed. 
2.3 Microbiological assay 
The quantitative determination of microbiologically active drug in plasma and 
urine was assessed by an agar diffijsion assay. The test strain used was Escherichia 
coli ATCC 25922 (Difco laboratories, U.S.A.). Following initial isolation, bacteria 
V 
� from a single colony were cultured on the agar slant overnight at 37°C. Prior to the 
assay, the bacteria were transferred to 5 ml ofMueller Hinton broth (MHB) to obtain 
an optical density equal to that of a 0.5 McFarland standard. Nutrient agar (Difco 
laboratories, U.S.A.) was poured in 14 cm x 14 cm agar plate (about 50 ml per plate) 
and mixed with 200 i^l of the bacterial suspension. Both MHB and nutrient agar were 
prepared as suggested by the manufacturer and sterilized by autoclaving before use. 
After the agar was set, six 6 mm diameter wells were punched evenly on the plate. 
The placement of the different samples was randomized to the wells. An exactly 
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measured volume of 50 i^l of plasma was introduced into each well. The urine 
samples were diluted with 0.05 M phosphate buffer (pH 7.35) (Joos B. et al., 1985). 
The following dilution factors were employed; 1:50 for samples collected over 0-2, 
2-4, 4-6 h intervals and 1:10 for 6-24 h interval. Concentrations (0.05, 0.1, 0.4, 0.8. 
1.5，3.0 ^ig/ml) in plasma standards were obtained by diluting stock solution with 
plasma free of any antibiotic. Concentrations (0.1, 0.8, 2.0, 4.0，6.0 [xg/ml) of 
ciprofloxacin in urine were used for calibration. Following the loading of samples, the 
plates were allowed to incubate at 37�C for 18 h. Inhibition zone diameters were 
measured by a digital caliper (Mitutoyo, Japan). Sample concentrations were 
intrapolated from the respective standard curves. 
The limit of ciprofloxacin detection was 0.05 ng/ml for both the plasma and 
urine assay. The assay was linear from 0.05 to 3.0 ^ig/ml for plasma. The regression 
equation describing the calibration curve for the plasma was y=2.1500x + 0.6448; r 
=0.9903 (Figure 2.6). Similarly, the calibration curve was also linear from 0.1 to 6.0 
|ag/ml for urine. The regression equation of the calibration curve for the urine assay 
was y=2.1504x - 0.2349;r=0.9939 (Figure 2.7). 
2.4 Discussion 
tf 
Ciprofloxacin in biological fluid can be determined by HPLC with ultraviolet 
« 




specific and sensitive and is preferable to more time-consuming and less specific 
microbiological methods. Moreover, microbiological methods also suffer from poor 
reproducibility and accuracy because active metabolites can interfere to give high 
results for the dmg. However, there are no significant differences in serum and urine 
ciprofloxacin concentrations measured by both the HPLC and M.A (JehI F. et al.， 
1985 and Morton S.J. et al., 1986). This observation suggests the contribution of 
antimicrobial activity of ciprofloxacin by its metabolites is negligible. 
Many HPLC procedures for ciprofloxacin do not use an internal standard 
(Jehl F. et al., 1985 and Weber A. et al., 1985). However, it is preferable to use one 
because it can compensate for errors that arise from any procedural loss of sample 
during sample treatment. Therefore, enoxacin was chosen as an internal standard in 
present study. A fluorescence detector shows more sensitive to be used for 
ciprofloxacin HPLC assay (Nix D.E. et aJ., 1985 and Weber A et al., 1985); 
however, it is not so sensitive to detect enoxacin as the detector wavelength set to 
suitable for detecting ciprofloxacin. Nevertheless, both ciprofloxacin and enoxacin 
show good absorbance at 278 nm, and thus the UV detector was chose for 
quantitation of ciprofloxacin. The conditions of HPLC method are different from the 
previous reports, i.e., to the mobile phase was added a few amount of triethylamine 
a 
and acetic acid to shorten the tails of ciprofloxacin and enoxacin (internal standard). 
The flow rate was set slower than those used in the previous studies because the 
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pressure of the column will be too high when the flow rate was faster. However, it is 
also an optimum flow rate result in an analysis time of only 11 min. 
The pharmacokinetic calculations of ciprofloxacin have carried out by using a 
M.A. in previous studies (Crump B. et al” 1983 and Brittain D.C. et al., 1985)， 
however, the active metabolites would interfere the results. Nevertheless, good 
correlation between M.A. and HPLC found for the assays of ciprofloxacin in serum 
and urine in previous study (Morton S.J. et al., 1986) and this study (Figure 2.8). 
This suggests that the concentrations of active metabolites of ciprofloxacin are too 
low to be measured by agar diffusion so we can ignore the difference between these 
two assays. Thus, the agar difRision test could estimate the antibacterial activity of 
ciprofloxacin and the HPLC assay could ensure accuracy of the analysis. Comparing 
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Figure 2.1 HPLC chromatogram of ciprofloxacin (B) and enoxacin 
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Figure 2.2 HPLC chromatogram of ciprofloxacin (B) and enoxacin 
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Figure 2.3 HPLC chromatogram of ciprofloxacin (B) and enoxacin 
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Table 2.1 Relative recovery of ciprofloxacin from plasma* 
Concentration Relative recovery Range 
(ng/ml) %Mean ± SD % 
1 0 0 6 2 . 1 士 1 . 2 6 0 . 4 - 6 4 . 2 
8 0 0 7 6 . 3 ± 2 . 8 7 1 . 7 - 8 0 . 2 
3 0 0 0 7 5 . 1 士 1 . 9 72.5 - 7 8 . 1 






Table 2.2 Effect of frozen storage on ciprofloxacin 
stability in rat plasma 
Added Measured concentration/ added concentration 
concentration (% for days) 
(ng/ml) 1 2 60 90 105 120 
50 105.4 97.6 99.6 106.6 105.4 99.2 
100 106.5 99.0 103.6 100.8 103.1 100.3 
400 100.6 99.1 100.6 99.3 103.5 100.9 
800 99.3 97.7 97.9 103.8 100.7 97.2 
• 1500 94.1 96.1 102.2 97.7 102.5 107.2 






The Effects of Oral Ferrous Sulfate on Pharmacokinetics and 
Pharmacodynamics of Intravenous Ciprofloxacin 
3.1 Introduction 
Ciprofloxacin is a second generation quinolone with a broad spectrum of 
antimicrobial activity. This antimicrobial agent can be given either by the oral or 
parenteral route. Ciprofloxacin administered orally is well absorbed and with good 
bioavailability (80%) in humans. Ciprofloxacin is intravenously administered to 
patients who are critically ill or in whom oral administration is not possible. However, 
a variety of medications containing metal cations have been shown to interfere with 
the bioavailability of ciprofloxacin and to cause alterations to its pharmacokinetic 
parameters O^ix D.E. et al., 1989a; Nix D.E. et al., 1989b; Frost R.W. et al., 1992 
and Lehto P. et al., 1994). A number of studies have investigated the influence of 
concurrent oral administration of ciprofloxacin and ferrous sulfate on the 
pharmacokinetics ofciprofloxacin (Polk R.E. et al., 1989 and Kara M. et al., 1991). 
The areas under the curve (AUC) and the peak plasma concentrations (Cmax) for 
0 
ciprofloxacin after an 500 mg oral dose were significantly reduced by 57% and 54%, 




elemental iron). The urinary recovery of ciprofloxacin was also decreased by 58% 
QLehto P. et al., 1994). The focus ofthese previous studies was confmed only to the 
situation when these two agents were coadministered simultaneously and their 
interaction was restricted in the gastrointestinal tract. 
Cation-ciprofloxacin interactions not only reduce the uptake of ciprofloxacin 
into the bloodstream but also antagonize the antibacterial activity of the drug (Lewin 
C.S. and Smith J.T., 1983). This is due to the cations chelating at the 3-carboxyl and 
4-0X0 functional groups of the drug which are also the site of antibacterial activity of 
the drug. Previous studies have shown that the mean MIC for ciprofloxacin increased 
over three-fold when magnesium was added to medium (Blaser J. and Luthy R., 
1988) and ferrous sulfate has also been reported to increase the MIC of test 
fluoroquinolones between 10- and 70-fold versus tested Gram-positive and Gram-
negative bacteria. Since concentrations of ciprofloxacin were only validated by HPLC 
assay in these studies, quantitation of the amount of ciprofloxacin was possible but 
the antibacterial activity of the antibiotic could not be identified when iron is present 
in the bloodstream. 
In the present study, the experimental design followed was that the rats were 
orally administered ferrous sulfate and this was followed by intravenous (i.v.) 
ciprofloxacin. Hence the interaction between the two agents, if any, could take place 
美 
in the bloodstream. In addition, biosamples i.e., plasma and urine collected were 
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quantified by both HPLC and micriobiological assays. Therefore，the data collected 
not only indicate the concentrations of ciprofloxacin in blood but also its antibacterial 
activity. These two assay systems should in principle discern the effects of metal 
chelate formation on the pharmacokinetics and antibacterial activity of the 
ciprofloxacin in vivo. 
3.2 Materials and Methods 
3.2.1 Chemicals 
Pure ciprofloxacin hydrochloride powder standard (potency 860 mg/g) was 
kindly provided by Bayer AG (Leverkusen, Germany). Stock solutions of 
ciprofloxacin at 100 ^ig/ml and enoxacin (internal standard) at 100 ^ig/ml (Sigma 
Chemical Co. U.S.A.) were prepared in deionized distilled water. Ferrous sulfate was 
BP grade (Wing Hing). HPLC grade acetonitrile (Mallinckrodt-Baker Inc., U.S.A.), 
V 
‘ methanol (BDH laboratory supplies, England) and acetic acid glacial (BDH 
laboratory supplies, England) were used for the preparation of chromatographic 
solvent systems. Analytical grade sodium dihydrogen phosphate monohydrate 
(Merck, Germany) and triethylamine (Riedel-de Haen AG, Germany) were also used 






Male Sprague-Dawley rats (body weight 200-250 g) were supplied by the 
Laboratory Animal Service Center of the Chinese University ofHong Kong and were 
used as study animals in this study. Ten rats were randomly assigned to two 
treatment groups for i.v. ciprofloxacin dosing (five rats per group, Group A and 
Group B). Each rat was lightly anaesthetized by ether and its right jugular vein 
cannulated with a polythene catheter (0.5 mm i.d., Portex Ltd, U.K.). The catheter 
was used for drug administration and blood sampling. Prior to drug dosing, animals 
were kept in individual metabolic cages and were fasted overnight with free access to 
water. Each rat in Group A received a 5 mg/kg i.v. bolus ciprofloxacin dose alone 
with an initial concentration 2 mg/ml. Blood samples (0.6 ml) were withdrawn from 
the catheter and were taken just prior to dosing (time=0), 5, 30，60，90, 120，150， 
180, 240 and 300 min following drug administration. Each rat in Group B was orally 
V 
• administered 100 mg/kg of ferrous sulfate immediately followed by the i.v. 
administration of bolus ciprofloxacin. Blood samples were obtained over the time 
schedule as outlined for Group A. After blood withdrawal, the plasma was 
immediately separated by centrifugation (Micro Centaur, MSE, Sanyo, U.K.) at 
10,000g for 5 min. The plasma was divided into two aliquots of 100 fil each. Urine 
samples were collected for 0 to 2, 2 to 4，4 to 6,.and 6 to 24 h intervals. The total 
volume of urine within each interval was recorded and an aliquot was taken for 
subsequent analyses for additional bioavailability analysis. Both plasma and urine 
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samples were stored at -80°C until analyzed. As previously determined, samples 
stored under this condition were stable for at least 4 months. One of the aliquots was 
used for the quantitation ofciprofloxacin using HPLC assay. The second aliquot was 
used for the assay of its antibacterial activity via an agar diffusion assay using 
Escherichia coli ATCC 25922 (Difco laboratories，Detroit MI, U.S.A.) as the test 
organism. Both assays were applied to the plasma and urine samples. 
3.2.3 HPLC assay 
For details of the HPLC assay for ciprofloxacin, please refer to Chapter 2 of 
this thesis. 
3.2.4 Microbiological assay 
The quantitative determinations of microbiological activity presented by 
ciprofloxacin in plasma and urine were made by an agar diffijsion assay. Please refer 
to Chapter 2 for details. 
3.2.5 Data Analysis 
The pharmacokinetic profiles for ciprofloxacin in individual rats were 
constructed by plotting the plasma concentration data against time. Non-
compartmental analysis was employed for the analysis of individual pharmacokinetic 
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profile. The distribution rate constant (A7) and the terminal elimination rate constant 
(A2) were estimated using log-linear regression on the distribution phase data and the 
post-distribution phase data, respectively. The associated elimination half-life (tm,x2) 
was calculated as ln2/ X2. Area under the plasma concentration versus time curve 
from time 0 to t (AUCo-t) was estimated using linear trapezoidal integration and 
extrapolation of area from t to infinity was represented by the term G / X2, where G 
is the last measurable plasma concentration. The total body clearance (Ch) was 
calculated as the i.v. dose divided byAUCo..^, Renal clearance (Cfc) was estimated as 
the total amount of ciprofloxacin recovered in urine divided hyAUCo.«. 
3.2.6 Statistical analysis 
Comparisons of the pharmacokinetic parameters obtained between the two 
study groups, i.e., with and without ferrous sulfate, for statistically significant 
differences were performed by the Student Mest. The level of statistical significance 






3.3.1 Data generated by the HPLC assay 
The mean plasma concentration v5' time curves for ciprofloxacin after bolus 
i.v. administration with or without oral ferrous sulfate dosing are shown in Figure 
3.1. Significantly higher plasma concentrations in the terminal phase occurred at 2 h 
post dosing in the group dosed with ferrous sulfate as compared to controls. The 
pharmacokinetic parameter estimates obtained for the two study groups are shown in 
Table 3.1. As compared to controls, AUCo-ao for ciprofloxacin was significantly higher 
for the group receiving oral ferrous sulfate dosing (1.89�土 0.15 i^g h/ml w 1.00�土�
0.39 jig hAnl，p <0.005). The tm,x2 estimate was 0.93 h for rats dosed with 
ciprofloxacin alone and was significantly Q?< 0.005) increased to 3.74 h with 
coadministraton of ferrous sulfate. The presence of ferrous sulfate reduced 
significantly (p< 0.05) both Ch and Ck by 51% and 46%, respectively. The 
distribution of ciprofloxacin as reflected by ( K a d increased from 1.47�土 0.34 L in 
control rats to 3.15�土 0.80 L in rats dosed with ferrous sulfate Q?< 0.005). There was 




3.3.2 Data generated by the microbiological assay 
The advantage offered by the microbiological assay (agar diffusion test) is the 
measurement of total antibacterial activity instead of ciprofloxacin concentration as 
measured by HPLC assay. 
When plotting the mean plasma concentration v5, time data obtained by the 
two assays in Group A，the profile generated by the microbiological assay (M.A.) 
was almost identical to that generated by the HPLC assay (Figure 3.2). The 
pharmacokinetic parameter estimates obtained by the two assays are shown in Table 
3.2, However, in Group B receiving both agents, the mean pharmacokinetic profile 
generated by the M.A. apparently disassociated from the profile generated by the 
HPLC assay 2 h after dosing (Figure 3.3). Since no significant differences in the 
pharmacokinetic parameters between the two assay for the control group (Group A) 
V 
(Table 3.2)，the ratios o£AUCo-oo and urinary recovery (microbiological : HPLC) 
were close to 1 (1.06 and 0.89, respectively) (Table 3.3). However, both theAUCo-ao 
and urinary recovery in Group B were significantly reduced as measured by the M.A. 
when compared to those of the HPLC assay (1.35�土 0.20 i^g h/ml v5 1.89�士 0.15 
|ig h/ml, p <0.005 and 0.31�土 0.09 mg v5 0.60�土 0.07 mg, p < 0.005, respectively). 
Therefore, the microbiological : HPLC ratios of AUCo^ oo and urinary recovery were 




Ciprofloxacin is known to form chelates with several metal cations and its 
bioavailability is reduced by concurrent administration with cations. Previous studies 
have shown a large reduction in AlJQv.. (57%) when ciprofloxacin was ingested 
along with ferrous sulfate (Lehto P. e1 “/., 1994). It was proposed that the formation 
of a poorly absorbed iron-ciprofloxacin complex in the gastrointestinal tract was the 
major mechanism for impairing the bioavailability of ciprofloxacin. 
The present study was designed in a way that ciprofloxacin and ferrous sulfate 
were administered by two different routes (intravenous and oral, respectively) to 
avoid physiological interaction between two agents in the gastrointestinal tract. 
Therefore, we can minimize the interference ferrous sulfate on ciprofloxacin 
absorption. Another study has sbown that oral ferrous sulfate can be readily absorbed 
from the gastrointestinal tract of the rat with a /'n^ ax of around 2 h (Geisser P. and 
Muller A., 1987). Iron in blood after absorption is transported by transferrin which is 
a pi-glycoprotein (Lamb D.J. et a/.,1994 and Richardson D. et a/.,1994). The 
binding of iron to transferrin is reversible because it only passes iron the molecule to 
erythroblasts for hemoglobin synthesis. Therefore, the binding of this complex might 
V 
not be too strong as compared to the formation of metal-ciprofloxacin complex. The 
chelation of iron-ciprofloxacin complex is strong as the dissociation constant of 
complex was measured to be 70.2|am (Ma H.H. e1"/., 1997). Therefore, iron bound 
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to ciprofloxacin should be stronger than transferrin. In fact, the decrease in activity as 
shown in the microbiological assay provides strong evidence to the above 
interpretation. 
Only limited data exist for the i.v. pharmacokinetics of ciprofloxacin in rats in 
the literature (Siefert H.M. et a/., 1986; Naora K. et al., 1990 and al-Khamis K.I. et 
al., 1994). Comparison of the present results with those published by others showed 
good agreement with respect to Ua.xi and U/2.x2 (al-Khamis K.I. et al., 1994). 
Moreover, the AUCo-的 was within a similar range (1.00�土 0.38 ^ig h/ml) and the 
urinary recovery was nearly identical 0.52 土 0.05 mg (Siefert H.M. et al., 1986). The 
plasma concentration ofciprofloxacin was found to declinebi-exponentially with time 
when the rats were intravenously administered ciprofloxacin. Ciprofloxacin was 
rapidly distributed after i.v. administration as shown by the value of the distribution 
half-life {Ui2M�： 0.38 h) during the distribution phase and by the decrease in the mean 
plasma level from 1.26 |ig/ml at 5 min to 0.39 ^ig/ml at 30 min i.e., about a three-fold 
reduction. This rapid distribution rate was accompanied by a large volume of 
distribution of ciprofloxacin (mean: 1,47 L). Urinary elimination of ciprofloxacin 
accounted for 49% of the dose by 24 h. 
m 
Results obtained in the present study with regard to the HPLC assay showed 




dosed with oral ferrous sulfate. The Ch and Ck tended to be reduced by 51% and 
46%, respectively. In the presence of ferrous sulfate, the terminal elimination half-life 
(tv2,x2) was prolonged by about 4-fold. Because of the changes observed for the 
pharmacokinetic parameters, ferrous sulfate appears to interfere with the 
pharmacokinetics ofciprofloxacin when the two agents are present in the blood. 
Comparing the data generated by both assays i.e., HPLC and M.A., there 
were no statistically significant differences Q) >0.05) between the two assays in the 
pharmacokinetic parameter estimates obtained for the control group. As with Group 
B, the concentrations of ciprofloxacin generated by M.A. were apparently lower 2 h 
after drug administration. Because the absorption of ferrous sulfate has been shown 
to the peak at 2 h (Geisser P. & Miiller A., 1987), the possibility of an interaction 
between the two agents in blood is high with iron concentrations also at high level， 
i.e., 2 h after ferrous sulfate was administered. Therefore, the concentrations of 
ciprofloxacin measured by M.A. for Group B rats were apparently lower after 2 h 
post dosing when compared to those measured by HPLC assay. This discrepancy 
indicates that an interaction between ciprofloxacin and ferrous sulfate can still occur 
in the blood when both are present simultaneously. Such reductions in the 
antibacterial activity of ciprofloxacin could be related to the forming of the iron-
ciprofloxacin complex which is pharmacologically inactive. 
The complex formed appeared to be more lipophilic than ciprofloxacin 
because Vd,u. increased about two-fold and Ch decreased about 51% in the presence 
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of iron. Because o f the higher lipophilicity, elimination of ciprofloxacin was reduced 
with its tm,x2. prolonged by 4-fold. 
The interaction between ciprofloxacin and ferrous sulfate is more complicated 
than just a physical interaction. The complexes formed can potentially increase the 
plasma concentrations of ciprofloxacin but at the same time reduce its antibacterial 
activity. Concentrations ofciprofloxacin, reported by HPLC detection might not be a 
true representation of the antibacterial activity. We cannot simply ignore the 
possibility of an interaction between quinolones given intravenously and metal cation 
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Figure 3.1 Mean (�土 SD) plasma ciprofloxacin concentration after 
i,v. bolus dose of 5mg/kg ciprofloxacin alone ( • ) and 
with lOOmg/kg orally administered ferrous sulfate (•)• 
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Figure 3.2 Mean ( 土 SD) plasma ciprofloxacin concentration after 
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Figure 3.3. Mean ( 士 SD) plasma ciprofloxacin concentration after a 
single i.v. bolus dose of 5mg/kg ciprofloxacin with oral 
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Chapter 4 
The Effect of Oral Ferrous Sulfate on Pharmacokinetics and 
Pharmacodynamics of Oral Ciprofloxacin 
4.1 Introduction 
Ciprofloxacin hydrochloride is rapidly and well absorbed from the 
gastrointestinal tract after oral administration. The absolute bioavailability is 
approximately 80% with no substantial loss by first pass metabolism and serum 
concentrations increase proportionately with the dose. 
Numerous reports have shown a variety of medications containing metal 
V 
cations, such as antacids and ferrous sulfate, can significantly impair the absorption of 
ciprofloxacin in humans QSTix D.E. et al., 1989b and Polk R.E. et a/.,1989). IhtAUC 
and peak plasma concentration of ciprofloxacin after an 500 mg oral dose were 
shown to be reduced by 57% and 54%, respectively, by oral ferrous sulfate 
administration (corresponding to 100 mg elemental iron). In addition, urinary 
recovery of ciprofloxacin was also decreased by 58%, and its 7max was observed 
slightly earlier when ciprofloxacin was coadministered with ferrous sulfate 0-ehto P. 
et a/.,1994). These previous studies mainly focused on the investigation of the two 
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agents when administered concomitantly such that they co-existed in the 
gastrointestinal tract. The formation of a poorly absorbed iron-ciprofIoxacin chelate 
has been proposed to be the major mechanism for such reduction in the absorption of 
ciprofloxacin. However, the impact of specific timing of ferrous sulfate administration 
in relation to ciprofloxacin on the absorption of the latter has not been reported. 
In the present study, the experimental procedures were designed such that the 
dosing time of the metal cation was taken into consideration to minimize direct 
contact of the two agents and to reduce the formation of the iron-ciprofloxacin 
complexes in the gastrointestinal tract. Thus, evaluation of the interaction between 
ciprofloxacin and ferrous sulfate in the bloodstream can be determined. We have also 
investigated the changes on pharmacokinetic parameters generated by HPLC assay 
and the changes of antibacterial activity of ciprofloxacin by microbiological assay 
(M.A.y � 
4.2 Materials and Methods 
4.2.1 Chemicals 
Pure ciprofloxacin hydrochloride powder standard (potency 860 mg/g) was 
kindly provided by Bayer AG ^>everkusen, Germany). Stock solutions of 
ciprofloxacin at 100 ^ig/ml and enoxacin (internal standard) at 100 ^ig/ml (Sigma 
Chemical Co. U.S.A.) were prepared in deionized*distilled water. Ferrous sulfate was 
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BP grade (Wing Hing). HPLC grade acetonitrile (Mallinckrodt-Baker Inc., U.S.A.), 
methanol (BDH laboratory supplies, England) and acetic acid glacial (BDH 
laboratory supplies, England) were used for the preparation chromatographic solvent 
systems. Analytical grade sodium dihydrogen phosphate monohydrate (Merck, 
Germany) and triethylamine (Riedel-de Haen AG, Germany) were also used in the 
development of the chromatographic assay. All reagents were commercially available. 
4.2.2 Animals 
Male Sprague Dawley rats (body weight 200-250 g) were supplied by the 
Laboratory Animal Service Center of the Chinese University ofHong Kong and were 
used as study animals in this study. Five rats in each group were used (Group C, 
Group D and Group E). Each rat was lightly anaesthetized by ether and its right 
jugular vein cannulated with a polythene catheter (0.5 mm i.d., Portex Ltd, U.K.). 
The catheter was used for the Hlood sampling. Prior the drug dosing, animals were 
kept in individual metabolic cages and were fasted overnight with free access to 
water. Each rat in Group C (control group) was administered a single 20 mg/kg oral 
dose of ciprofloxacin alone. Blood samples (0.6 ml) were withdrawn from the 
catheter and were taken just prior to dosing (time=0) and at 5，30’ 60，90，120, 150, 
180, 240，300 and 360 min following drug administration. Each rat in Group D was 
r 
orally administered a 100 mg/kg dose of ferrous sulfate 75 min after oral 
ciprofloxacin dosing. For Group D，blood samples (0.6 ml) were withdrawn just prior 
63 
to dosing and at 5, 30，60，75 (before oral dosing ferrous sulfate), 90，120, 150, 180， 
240，300 and 360 min following ciprofloxacin administration. For another group of 
rats (Group E), the rats were orally administered a 100 mg/kg dose of ferrous sulfate 
2 h before 20 mg/kg of oral ciprofloxacin. Blood samples (0.6 ml) were then taken 
just prior to dosing ferrous sulfate and before oral dosing ciprofloxacin, and then the 
same time intervals as employed in Group C. After blood collection, plasma was 
immediately separated by centriftigation (Micro Centaur, MSE, Sanyo, U.K.) at 
10,000g for 5 min. The plasma was then divided into two aliquots of 100 “1 each. 
Urine samples were also collected at of 0-2, 2-4, 4-6，and 6-24 h intervals. Total 
urine volume within each interval was recorded and an aliquot was taken for 
quantitation of ciprofloxacin in order to obtain additional information on 
bioavailability. Both plasma and urine samples were stored at -80° C until analyzed. It 
has been determined in our preliminary study that these samples would be stable for 
at least 4 months under this storage condition. One of the aliquots was used for the 
analysis of ciprofloxacin using HPLC assay. The second aliquot was assayed for its 
antibacterial activity via an agar diffusion assay using Escherichia coli ATCC 25922 
(Difco laboratories, Detroit MI, U.S.A.) as the test organism. With these 
measurements a contrast between drug concentrations and antimicrobial activity in 




4.2.3 HPLC assay 
The HPLC assay for measuring the concentrations of ciprofloxacin is 
described in detail in Chapter 2. 
4.2.5 Microbiological assay 
The quantitative determinations of microbiological activity presented by 
ciprofloxacin in plasma and urine were made by agar diffusion assay. Please refer to 
Chapter 2 for details. 
4.2.6 Data Analysis 
The pharmacokinetic profiles for ciprofloxacin in individual rats were 
constructed by plotting th^ plasma concentration data against time. Non-
compartmental analysis was employed for the analysis of individual pharmacokinetic 
profile. Maximum plasma concentration (Cmax) and the time at which Cnax was 
observed (Tmax) were directly obtained from the data for each animal. The terminal 
elimination rate constant {X2) was estimated using log-linear regression on the post-
distribution phase data. The associated elimination half-life (/1/2,u) was calculated as 
ln2/ X2. Area under the plasma concentration versus time curve from time 0 to t 
(AUCo-t) was estimated using linear trapezoidal integration and extrapolation of area 
« 




concentration. The total body clearance (C/j) was calculated as the oral dose times 
bioavailability divided by AUCo--. Renal clearance (C/R) was estimated as the total 
amount of ciprofloxacin recovered in urine divided by^f7Co.«. 
The relative bioavailability for each rat was calculated by comparing the 
AUCo-c^ for ciprofloxacin concomitant with ferrous sulfate to the average ofAUCo^ 
from the control group. 
4.2.7 Statistical analysis 
Statistical comparisons between any two treatment groups with respect to 
AUCo.^, Cmax, terminal half-life (tv2,x2),『腿，Ch, Ck and urinary recovery were 
performed using the Student Mest. Statistically significant differences were 
considered set at the level of 0.05. Pharmacokinetic parameter estimates are 
V 
presented as mean 士 SD. 
4.3 Results 
4.3.1 Data generated by the HPLC assay 
The mean plasma concentration-time profiles for ciprofloxacin obtained by 
• 
HPLC assay after oral administration alone (Group C), coadministration with ferrous 
sulfate 75min after oral ciprofloxacin dosing (Group D) and 120 min before (Group 
美 
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E) before ciprofloxacin dosing are presented in Figure 4.1. The relative 
bioavailabilities of Group D and Group E were 73% and 27%，respectively. The 
AUCo-co decreased by 73% in Group D compared to the control group (0.54�土 0.22 
^ig h/ml v5 1.97�土 0.51 |ig h/ml, p <0.005) but no statistical difference in Group D 
(1.42�土 0.04 ^ig h/ml Kv 1.97�土 0.51 ^ig hAnl) was found. A summary of the mean 
pharmacokinetic parameters of ciprofloxacin following each treatment are shown in 
Table 4.1. There was no significant difference in the pharmacokinetic parameters 
between Group C and Group D, except a long terminal elimination half-life {tmxd 
was observed (1.96�土 0.43 h vs, 2.80�土 0.11 h, p <0.05) in Group D. The results 
showed that oral ciprofloxacin 120 min after ferrous sulfate (Group E) caused a 
significant decrease in AUCo-” Cmax and urinary recovery by 76，91 and 68%, 
respectively. In addition, T^ ax was also delayed. 
4.3.2 Data generated by the microbiological assay 
Data collected using the HPLC assay were compared to that obtained by the 
microbiological assay (agar diffiasion test) for the detection of discrepancies between 
antibacterial activity and ciprofloxacin concentrations. 
The mean pharmacokinetic parameters of ciprofloxacin generated by M.A. in 
each treatment are shown in Table 4.1. There was also no significant difference in the 
« 
pharmacokinetic parameters between Group C and Group D. In the control group 
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(group C), the mean concentration-time curve generated by HPLC assay was almost 
overlapped by the curve generated by the microbiological assay (M.A.) (Figure 4.2) 
and there were no significant differences in the pharmacokinetic parameters between 
the two assays, i.e., the concentrations of ciprofloxacin detected by HPLC were 
equivalent to the antibacterial effect of the antibiotic. The ratios ofM.A. to HPLC 
assay for AUC\^, C,nnx and urinary recovery were 0.92, 0.93 and 0.96, respectively, 
and were close to unity. In Group D, both of the A U C ^ and urinary recovery 
showed statistically significant differences (p <0.05) between M.A. and HPLC assay, 
however Cmax did not show any significant difference between the two assays (Figure 
4.3). The ratios ofM.A. to HPLC assay forAUCo--, (了,舰 and urinary recovery were 
c 
0.91, 0.86 and 0.65, respectively. For Group E, not only the AUCo.^ and urinary 
recovery were lowered but (：；職 was significantly lower as measured by the M.A. in 
comparison with the HPLC assay (Figure 4.4). Therefore, the ratios of M.A. to 
HPLC assay for AUCo--, C™x and urinary recovery were 0.49’ 0.61 and 0.62, 
respectively. These ratios were significantly less than one (Table 4.2). 
4.4 Discussion 
Ciprofloxacin is known to chelate with metal cations. The manufacturer, 
therefore, recommended that ciprofloxacin should be dosed 2 h before or 6 h after 
oral administration of antacids (Nix D.E. et aJ., 1989b). A previous study has shown 
that a large reduction in AUCo-^  and Cn,ax of ciprofloxacin when the antibiotic was 
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orally coadministered with ferrous sulfate (Nix D.E. et al., 1989b and Polk R.E. et 
al,, 1989). However, there has been no study to consider the influence o f t h e spread 
of dosing times between the two agents on ciprofloxacin absorption and 
pharmacokinetics. In the present study, ferrous sulfate was given 75 min after oral 
dosing ciprofloxacin (Group D) because the average r^ax for ciprofloxacin was 30 
min or less in rat. This approach would have minimized the probability of direct 
physical interaction between the two agents as ciprofloxacin would mostly be 
absorbed by then. The data generated by the HPLC assay appeared not to show any 
significant differences in the pharmacokinetic parameters between the control group 
and Group D; with the exception that / 即 was prolonged in Group D. These results 
may be misleading in the sense that when cations were given after an adequate time 
interval following oral ciprofloxacin dosing, the bioavailability of ciprofloxacin would 
not be affected and therefore a similar degree of antibacterial activity should be 
obtained. However, there was ^n apparent discrepancy when the data were compared 
between the two assays. In Group D, both the/lf/Co-.. and urinary recovery generated 
by the microbiological assay were lower when compared to that obtained by the 
HPLC assay. Interesting, there was no significant difference in ('max- This observation 
indicates that ferrous sulfate following its absorption in the gastrointestinal tract 
might interact with ciprofloxacin in the bloodstream at a later time and thereby 
¥ 
prolong the half-life for ciprofloxacin. The cation is believed to chelate ciprofloxacin 
at the 4-oxo-3-carboxylic acid site which is also believed to be the site for 
* 
antimicrobial activity of antibiotic. This is in agreement with the decrease in 
69 
� Chapter 4 
antibacterial efficacy. Therefore，ciprofloxacin concentrations detected by the HPLC 
assay may not indicate the anticipated degree of equivalent to antibacterial activity. 
In a separate group of animals, ferrous sulfate was given 120 min before oral 
ciprofloxacin dosing. This design aimed at allowing the concentrations of ferrous 
sulfate in the systemic circulation to be at a maximum at the time of ciprofloxacin 
dosing. Similarly, with rapid absorption of ciprofloxacin, the interaction between the 
two agents would be studied at their maximum concentrations in blood. Results 
showed that the AUCo-�C_x and urinary recovery were significantly decreased for 
rats in Group E. The decreased A U C � � ’ C n^x suggests that an amount of ferrous 
sulfate has not been completely absorbed within 2h. Moreover, the bioavailability of 
ciprofloxacin also significantly decreased by 73%. Although a lesser amount of 
ciprofloxacin was absorbed, the decrease in antibacterial activity was more substantial 
as suggested by the lower ratios ofM.A. to HPLC assay forAUCo.^, Cmax and urinary 
recovery (Table 3.2). In conclusion, the interaction between ciprofloxacin and ferrous 
sulfate not only occurs in the gastrointestinal tract by reducing the bioavailability of 
ciprofloxacin but also causes an inactivation of the antibiotic in the systemic 
circulation. Therefore, coadministration of ciprofloxacin and ferrous sulfate should be 
carefully controlled. Particularly, even though when ferrous sulfate is given an 
adequate time interval prior to ciprofloxacin dosing, the ferrous sulfate absorbed can 
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Figure 4.1 Mean (�士 SD) pIasma concentrations of oral dosing 
20mg/kg ciprofloxacin aIone ( •)，75min before 
lOOmg/kg ferrous sulfate (•)，and 120min after 




1000 - i ^ V 
！ f ^ H ^ 





1J 1 1 1 1 1 “ 
0 1 2 3 4 5 6 
Time (h) 
Figure 4.2 Mean (�土 SD) plasma concentrations oforal dosing 




� Chapter 4 
1 0 0 0 0 丁 
1000 -- J 
} p V ^ 
I 1 0 0 " ^ ^ " ^ t = ^ ^ = ^ j _ 丁 




etf s 10 - -
V 
> 
l J — 1 1 ' 
0 2 4 6 
Time (h) 
» 
Figure 4.3 Mean ( ±"SD) plasma concentrations of orally dosed 
20mg/kg ciprofloxacin 75min before oral dosing 
lOOmg/kg ferrous sulfate generated by M.A. ( • ) and 
HPLC (•)• 
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‘Figure 4.4 Mean (�士 SD) plasma concentrations of orally dosed 
20mg/kg ciprofloxacin 120min after oraI dosing ferrous 
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Influence of Mineral Rich Traditional Chinese Medicines on the 
Pharmacokinetics ofOral Ciprofloxacin 
5.1 Introduction 
Traditional Chinese Medicines (TCM) have been used for thousands ofyears 
by a large population in Asia. The use ofTCM provides much of the health care need 
for the Chinese people and still is enjoying a high degree of confidence in China 
which parallels that of modern Western pharmacotherapy. The sources of TCM are 
from plants, animals and minerals, and most of them are of plants origin, as there are 
\-
- over 7,000 species of medicinal plants in China (Chung-kuo et al., 1989). Because 
TCM is available to the public for self-medication purposes, coadministration of 
TCMs with Western medicines is more commonly seen in Chinese people. In China, 
TCMs are used as an alternative medical treatment or supplemental treatment in 
conjunction with western medical treatment. The use of TCMs is particularly 
common for chronic diseases. Because of the wide varieties ofTCMs，it is anticipated 
that interactions between TCMs and western medicines should exist. 
« 
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Many previous reports have shown that oral absorption of quinolones is 
reduced by coadministration of preparations containing metal cations and minerals 
OFrost R.W. et aL, 1992; Lehto P. et al., 1994 and Kanemitsuk K. et al, 1995). A 
number of herbs are known to contain a large amount of minerals，thus, these crude 
drugs are likely to interfere with the absorption and bioavailability of ciprofloxacin. In 
the present study, we have evaluated the interactions between ciprofloxacin and four 
selected TCMs i.e., Sanguisorba officinalis L., Foeniculum vulgare Mill,, 
Taraxacum mongoUcum Hand. Mazz. and Cinnabaris，on the pharmacokinetics and 
bioavailability of ciprofloxacin using a standardized experimental design. 
5.1.1 Sanguisorba officinalis L (地榆）�
The dried roots and rhizomes of Sanguisorba officinalis L. (SO) OFigure 5.1) 
ofRosaceae are commonly usedfor the treatment ofhemoptysis, epistaxis, dysentery, 
hemorrhage, functional bleeding and for the external treatment of scalds，snake and 
insect bites, and burns. Its antibacterial activities have been documented as its 
decoction is able to inhibit growing of Pneumoniae bacilli, Pseudomonas 





1 • Saponin: sanguisorbin (upon hydrolysis yields sanguisorbigenin, or tomentosolic 
acid), ziyuglycosides I, II (which yield promolic acid upon hydrolysis) 
2 • Tannins 17% (catechol type)，vitamin A 
3 • Metal cations; such as iron (479.5 ^ig/g), calcium (10846 \xglg) and magnesium 
(2629 ^igy^. 
5.1.2 Foeniculum vulgare Mill. ( /』、茴香) 
The dried mature fruits oiFoeniculum vulgare Mill. OFV) (FigarQ 5.2) of the 
Umbelliferae family are used for the treatment of abdominal distention, vomiting, 
diarrhea, hemia, abdominal pain and asthma ^Isu H-Y et al., 1986). 
»： 
Chemical constituents: � 
1 . Essential oils (3-8%): anethaI 50-60%, estragole, c/-limonene, /-limonene, d-
fenchone, c/-pinene, dipentene and anisadehyde; 
2 . Proteins (20%) 
3 . Fatty oils (12-18%) 
4 • A variety ofmetal cations including iron (260.4 ^ig/g), calcium (6754 ^ig/g) and 
* 0 
magnesium (6092 |ig/g). 
^ 
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5.1.3 Taraxacum mongolicum Hand. M a z z . (蒲公英) 
The whole herb of Taraxacum mongolicum Hand. Mazz. (TM) of 
Compositae (Figure 5.3), possesses strong anti-inflammatory effect and commonly 
used for the treatments ofbreast abscess, acute appendicitis, sorethroat, conjunctival 
congestion and jaundice. Its decoction exerts a bacteriostatic effect on 
Staphylococcus aureus, Streptococcus hemolyticus, etc., and its in vitro antifungal, 
anti-leptospiral and antiviral effects have been documented. The herb is used for the 
treatment ofupper respiratory tract infection, gastritis, enteritis, relief of cholelystitis 
and abdominal pain in clinical practice (Hsu H-Y et al, 1986 and Ou M.et al, 1994). 
Chemical constituents: Taraxasterol, choline, inulin, pectin, taraxacin, taraxarol, 
asparagin, and a variety of metal cations including iron (2311 ^ig/g), calcium (4941 
^ig/g) and magnesium (5760 ^igy^). 
5.1.4 Cinnabaris (朱砂）�
Cinnabar ore, chiefly containing hydrargyrum sulfide OHgS) ^Figure 5.4) 
possesses anti-inflammatory and tranquilizing effects. It is used for the treatments of 
irritability, insomnia, palpitation, epilepsy and manic depressive syndrome. It is 




substance contains 86.2% of mercury and 13.8% of sulphur (Hsu H-Y et al, 1986 
and OuM. etal., 1994). 
5.2 Materials and Methods 
5.2.1 Chemicals 
Pure ciprofloxacin hydrochloride powder standard (potency 860 mg/g) was 
kindly provided by Bayer AG (Leverkusen, Germany). Stock solutions of 
ciprofloxacin at 100 i^gAnl and enoxacin at 100 ^ig/ml (Sigma Chemical Co. USA) 
were prepared in deionized distilled water. The TCM (including SO, FV, TM and 
Cinnabaris) were purchased from local herbal drugs store. HPLC grade acetonitrile 
(Mallinckrodt-Baker Inc.，USA), methanol (BDH laboratory supplies, England) and 
acetic acid glacial (BDH laboratory supplies, England) were used for the preparation 
chromatographic solvent systelms. Analytical grade sodium dihydrogen phosphate 
monohydrate QAerck, Germany) and triethylamine (Riedel-de Haen AG, Germany) 
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5.2.2 Preparation ofTCM extract 
Powdered SO (5 g) was extracted by boiling water (50 ml) for 1 h. After 
cooling, the solution was filtered and concentrated to 10 ml to make the finai 
concentration of the aqueous extract being 500 mg/ml. The same procedures were 
used for the preparation ofFV, and TM extracts. 
Cinnabaris was grounded into fine powder with gradually adding deionized 
distilled water. The final concentration of the preparation was 50 mg/ml. 
5.2.3 Animals 
Male Sprague Dawley rats (body weight 200-250 g) were supplied by the 
Laboratory Animal Service Center of the Chinese University ofHong Kong and were 
used as study animals in this study. Five rats in each group was used. Each rat was 
lightly anaesthetized by ether and cannulated through its right jugular vein with 
polythene catheter (0.5 mm i.d.，Portex Ltd, U.K.). The catheter was used for the 
blood sampling. Prior to drug dosing, animals were kept in individual metabolic cages 
and were fasted overnight with free access to water. In each test rats were dosed with 
r 
200 mg/kg of the plant aqueous extract, i.e., SO, FV, TM, or Cinnabaris orally 
followed by oral dosing of20mg/kg ciprofloxacin. The test groups were identified as 
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Group M, N, 0，and P, respectively. The rats in control group (Group C) were only 
given a dose of 20mg/kg of ciprofloxacin alone. Blood samples (0.6 ml) were 
withdrawn from the catheter and were taken just prior to dosing (time=0) and at 5， 
30，60，90，120, 150, 180，240，300 and 360 min following concomitant drug 
administration. After blood withdrawal, plasma was immediately separated by 
centrifugation (Micro Centaur, MSE, Sanyo, U.K.) at 10,000g for 5 min. A 1000 
aliquot of plasma was removed for storage. Urine samples were collected over 0-2， 
2-4，4-6，and 6-24 h intervals; the total volume within each interval was recorded. An 
aliquot was taken for subsequent HPLC assay. Both plasma and urine samples were 
stored at - 8 0 � C until assayed. 
5.2.4 HPLC assay 
The HPLC assay ofciprofloxacin was described in details in the Chapter 2 of 
this thesis. 
5.2.6 Data Analysis 
The pharmacokinetic profiles for ciprofloxacin in individual rats were 
constructed by plotting the plasma concentration data against time. Non-
compartmental analysis was employed for the analysis of individual pharmacokinetic 
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profile. Maximum plasma concentration (C^ax) and the time at which Cmax was 
observed (r^x) were directly obtained from the data for each animal. The terminal 
elimination rate constant {X2) was estimated using log-linear regression on the post-
distribution phase data. The associated elimination half-life {h12,x2) was calculated as 
ln2/ X2. The area under the plasma concentration versus time curve from time 0 to t 
{AUC.Q.^  was estimated using linear trapezoidal integration and extrapolation of area 
from t to infinity was represented by the term C,/ A2, where C, is the last measurable 
concentration. The total body clearance (C/x), was calculated as the oral dose timed 
bioavailability divided by AUCo-的.Renal clearance (Ck) was estimated as the total 
amount of ciprofloxacin recovered in urine divided byAUCo-^. 
The relative bioavailability for each subject was calculated by comparing the 




5.2.7 Statistical analysis 
Statistical comparisons between the TCM groups and control group with 
respect to A U C o � C.ax,厂匪，terminal half-life (iu2,x2l (¾, ( ¾ and urinary recovery 
were performed using the Student Mest. The differences were considered to be 
statistically significantly at the a level of 0.06. Pharmacokinetic parameters are 
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presented as mean 士 SD. 
5.3 Results 
The mean plasma concentration-time profile of ciprofloxacin for the control 
group (Group C)，and those with concomitant oral administration with SO, FV, TM 
and Cinnabaris, i.e., Group M, N，0, and P, are shown Figure 5.5a-d. The^f7Co-oo for 
ciprofloxacin was significantly reduced by 78% (0.43 土 0.07 ^g h/ ml v^y 1.97 士 0.51 
^ig hi ml, p <0.005) when the antibiotic was concomitantly administered with SO. As 
compared to control, FV resulted in a reduction of the AUCo.oo by 48% (1.02 土 0.21 
|ig hy^  ml V5 1.97 士 0.51 i^g h/ ml, p <0.05). The pharmacokinetic parameters of 
ciprofloxacin obtained in each treatment group are shown in Table 5.1. There were 
no statistical significant differences (p >0.05) in any of the pharmacokinetic 
parameters obtained between Group C and Group P with the exception that the 
terminal half-life (fmM) in Group P was prolonged for 58% (3.09 土 1.29 h v5 1.96 士 
0.43 h, p <0.005). These results showed that there were apparent alternations in the 
pharmacokinetics of ciprofloxacin when the rats received ciprofloxacin concurrently 
with SO; AUCo-泊,Cmax and urinary recovery for ciprofloxacin were decreased by 78， 
94 and 79%, respectively. The terminal half-life of ciprofloxacin with SO dosing was 
also longer than that observed in the control group (3.78 土 1.36 h V5 1.96 土 0.43 h, p 
<0.05). In addition, T^^ was delayed by SQ administration. In Group N, FV 
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decreased the AUCo^ Cnax and urinary recovery of ciprofloxacin by 48, 82 and 
44%, respectively. Similarly, the terminal half-life was also longer than that ofcontrol 
group (5.23 土 2.05 h vi' 1.96 土 0.43 h, p <0.05) but with no effect on 7;,ax. For the 
animals in Group 0，TM decreased (:隱 ofciprofloxacin by 73% (0.35�士 0.04 ^ig/ ml 
vs 1.31 土 0.49 \i^ ml, p <0.005), but with no significant changes in AUCo.^ and 
urinary recovery. The terminal half-life was also prolonged about 2.79-fold (5.71 士 
0.91 h us, 1.96 士 0.43 h, p <0.005) when TM was given concurrently. No effect on 
the 7;,ax was observed. The relative bioavailability of ciprofloxacin in the presence of 
SO, FV，TM and Cinnabaris were 22, 52, 96 and 86%, respectively. No significant 
changes …>0.05) in the total body clearance (C/x) and renal clearance ( (¾) when 
ciprofloxacin was coadministered with these TCMs. 
5.4 Discussion 
V 
Previous studies have demonstrated that the absorption of orally administered 
ciprofloxacin can be impaired by concomitant administration of agents containing 
metal cations. The relative bioavailability of ciprofloxacin can be reduced by 40% 
when given with calcium carbonate (Frost R.W. et (//., 1992). The AUC of 
ciprofloxacin has been shown to decrease by 57% when the antibiotics was dosed 
concomitantly with ferrous sulfate (Lehto P. et al.�1994). However, the negative 
effect of metal cations on the absorption of ciprofloxacin has been restricted to the 
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areas of modern western medicines containing metal cations in the previous studies. 
The present investigation is the first to evaluate the effects of TCMs 
containing a high amount of minerals on the pharmacokinetics and bioavailability of 
ciprofloxacin. Because of the high mineral content, these TCMs are expected to 
interfere with the absorption ofciprofloxacin. Coadministration of the three herbal of 
TCMs significantly decreased the plasma concentrations and urinary recovery of 
ciprofloxacin to different extents which followed the decreasing order of SO > FV > 
TM. Both SO and FV exhibited marked effects on reducing the AUCo-ao^  Gmx and 
urinary recovery of ciprofloxacin. This observation strongly suggests that oral 
ciprofloxacin with concomitant administration of SO or FV could significantly 
impaired the absorption of ciprofloxacin. Therefore, the use of ciprofloxacin should 
be spaced with a sufficient time intervals between these two agents. Because SO also 
V 
demonstrates an antibacterial activity, the likelihood of using SO in conjunction with 
ciprofloxacin is especially high. 
In the case of TM, the possible consequences of such interaction with 
ciprofloxacin are less clear. The extent of absorption of ciprofloxacin was only 
moderately reduced by coadministration with TM, i.e. the AUCo.^  and urinary 
recovery did not show any significant differences. However, this interaction resulted 
in almost a 73% reduction in the peak plasma ciprofloxacin concentrations. 
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Therefore, it may still be necessary not to coadminister ciprofloxacin with TM. 
Finally, there was no significant influences on the pharmacokinetic parameters 
of ciprofloxacin when Cinnabaris was given concurrently with ciprofloxacin except 
with a longer terminal half-life. From a theoretical point of view, this lower degree of 
interaction is expected because Cinnabaris is only slightly soluble in water. The free 
Hg2+ content from Cinnabaris was not adequate for chelation with ciprofloxacin in 
the gastrointestinal tract. On the other hand, if the Hg2+ content was high, the drug 
would have been highly toxic. 
These results show the existence of a significant pharmacokinetic interaction 
between three herbal TCMs (SO, FV, TM) and ciprofloxacin. Oral absorption of 
ciprofloxacin was greatly impaired by these TCMs. This interaction may be a result of 
formation of cation-ciprofloxacin complex. Furthermore, TCM may also possess a 
variety of unidentified ingredients which may also interfere the absorption of 
ciprofloxacin. Thus, the coadministration TCMs (especially for those with a high 
mineral content) with ciprofloxacin is not recommended. 
• 
88 
^ ^ ^ ^ ^ ^ ^ E ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ I ^ ^ ^ ^ ^ • p
 j
 _ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ H I ^ ^ ^ ^ ^ ^ ^ ^ H 
















< I ^ ^ B " ^ P ^ H H ^ ^ ^ ^ ^ I 
^ ^ ^ ^ ^ ^ ^ ^ I ^ H r v J
 ^
 _ ^ ^ ^ ^ ^ ^ ^ H j ^ ^ ^ ^ ^ ^ A ^ ^ ^ ^ H F ^ H ^ B ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ m .
 . 、 < ? . 、 書 #




















^ ^ ^ ^ ^ ^ ^ ^ 1 ^ 1
 -
 ;
 \ ^ .
 - _
 -
 - I ^ ^ ^ ^ ^ ^ ^ A .
 - ^ ^ ^ 9
 . ^ ^ H ^ ^ ^ ^ I M ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 




 _ ^ ^ B ^ . 7




 : . . : : V ; 。 “ ： . 「 . V : 」 > F . . .
 • ^ ^ ^ . ^ ^ ^ . . ^ V . ^ ^ I H ^ ^ ^ ^ ^ ^ ^ I 
^ ^ I H
 f / 霊 露 囊 養 藝 " 、 • : ;
 _ b i s ^ ^ H H ^ ^ ^ H 
^ ^ ^ ^ ^ ^ ^ H ^ I
 .
 i ^ < , ^ ^
 . '
 ；
 I ^ ^ ^ ^ ^ ^ ^ ^ ^ H - ^ ^ ^ ^ ^ ^ P - ^ ^ ^ ^ H ^ B R ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ I 
^ • 圓 . ， ， ％ 奢 着 顏 扇 霞 「 4 衣 脅 H ^ y p ^ s H H ^ ^ I ^ ^ ^ 1 1
� & 巻 身 € 另 爹 3 ( 冗 . . 一 。 ： 〉 〈 . " | 「 字 一 ， " " ( ： ) V ， H ^ ^ ^ ^ V ^ M ^ ^ P ^ H H 8 n H ^ ^ ^ I 
^ ^ ^ ^ ^ l l - .
 J / ^ / -
 . ¾ ^ ^ ^ . ^ . ^ . ^ . ¾ ^ /
 ^ % p v ^
 l . i : . ^ 。 -
 _
 r ‘





























 V 7 .
 . , : . . +
 I ^ ^ H . . ^ ^ ^ ^ ^ ^ F ^ J A I _ ^ H ^ ^ ^ B . ^ ^ ^ ^ ^ ^ ! 
^ ^ • 1
 § A > "
 , : _ ^ & S ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ • 、 ： ^ , ? 露 | ” . 言 ： 稿 ： 9 : : . ^ 、 ： ； / ? ^
 
. • ^ B ^ ^ ^ . M ^ ^ ^ I V B I ^ ^ ^ ^ ^ ^ I 
^ ^ ^ ^ ^ ^ I ^ H .
 : ^ . ^ . ' r
 -
 _ ^ ^ ^ K ^ ^ ^ m ^ ^ ^ ^ ^ ^ H ^ H ^ & ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ ^ ^ ^ ^ ^ • ^ 1 .
� : . 二 \ 、 . � . ， .
 < K ^ l a B ^ ^ ^ ^ ^ ^ f l f l l ^ ^ s ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ ^ ^ ^ ^ H ^ H
 ;
 -
 \ . \ ;
 < ^ , A , " . . > J .
 :
 “
 y H ^ ^ -
 M ^ ^ ^ ^ ^ ^ F . ^ ^ ^ ^ ^ ^ ^ ^ ^ I ^ V ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ ^ ^ ^ ^ • ^ ^ ^ • 1
 r , ^ r . - _
 : ( - ( / . , < 、 . - . . \ / - ^
 V V ^ I ^ ^ ^ H
 / ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m - ^ ^ K ^ ^ ^ ^ ^ ^ ^ I ^ P l ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ l 
^ • • 4
 :
 . ^ . . V ^ . ^ P M M V H _ A H ^ ^ ^ ^ ^ H 

















^ ^ ^ ^ • • 厂 ： . . _ / : > \ ^ 斤 1 爹 ， 一 勢 〕 ？ ： . . ， / 墓 、 J . . .
 > / ' H ^ ^ ^ ^ _ ^ ^ ^ ^ ^ I ^ ^ B R ^ ^ ^ ^ ^ ^ ^ H 
^ ^ • • # $ : ^ 謹 象 蒙 ： h ’ > : : .
, m p l p i ^ s n ^ ^ ^ H 
^ ^ • • 雾 舊 舊 _ 霧 “ ： 繁 ， $
� “ ， .
 H ^ ^ ^ ^ ^ ^ ^ I ^ ^ ^ ^ ^ H 
^ ^ • • 1
 ¢ , 1 , - ¾ / ) ： ： . . ： ： ： . - : . ,
 -
 - M ^ ^ B ^ ^ ^ ^ B ^ ^ ^ ^ ^ B 
H E 
^ ^ ^ ^ .^- ) .>_ v ^ ' - - A ^ \ ^ ^ B 
^ ^ ^ ^ ^ H .^ &.- -^=ip^� 、，<,� \ ^^M 
^ ^ ^ ^ ^ ^ - . 1\ l / \ ^ ^ 
^ ^ H - ¾ ; :, ^ . ¾ ^ . . t ^ ^ U ' , t iX-w^ •{ r� 梦� •�^^^^^M ^^；^ ^v%-^^'U • . ^ ^^_^:,^rm^:^ ! : WL， j� -一 T � ^ H 
^ B� ^� ^ , ¾ , . ' ¾ ^ ¾ ^ ¾ ¾ ^ ,� \ . _ . � 等 圓�
^ ^ > ， 身 身 ^ ^ ^ ^ ^ ^ | 8 1 ^ « ^ . _ 還 •�




^^ ^^ ^^ •^:广'^ ^^ 、劣 "^!^ �箱多>-泛紅、鶴1.>".鄉‘ i^^^" ‘••.命：莉.:v^l u-- ^ ^^¾?--. •�；•：>" -:^'¢5^¾¾^ V-- ' , .^^H ^ ^ ^ ^ ^ H� ； :^义^^ ^^ ：^^ 麵&^ ?^ #辦‘：^^ ^年。為.;丨.;、1^  1 : ^ ¾ ¾ ¾ ^ ? ? ¾ * ¾ ^ " ¾ ¾ ^ ^ ? ^ ^ ^ ¾ 
^H s^iwK^^ fci_feaawp_ 
^ ^ ^ ^ . : . : 够 雞 穴 _ _ ； ^ # ^ ^ ^ ^ . 〗 , 辑 趟 4 ^ 識 : : - 巧 : : 、 薄 肆 : - ^ M 
^^^^^^^^^M 1. -^ .i^-'> ; i ^.?^^i^-^'^^>1> '*-i-/ :i:i^ V^ sO^ -.j^ >^- '-.'f-, - ^^^Jp ?--^-' ••• -^^'- -o .^^  ''. ^^^^^H 
^ ^ ^ ^ H v,^.,\- : : . ;¾--:^-¾^¾-^^^?^;;^:^^:-
^ ^ ^ H _ . : 3 _ 料 _ _ . 拜 碧 麵 _ : : :� , 〕 ^ » & : 竊 : _ 養 _ 1 : � ^ > 
^^^^m�.-:,...�:^^.*rc:^-_，,'::％h.�.:"^t^.�:^,.H^ <y^:�？茂:?.:煤::;^® 
^ ^ ^ ^ • . y - -/,V:^ :.^ r^^ -^:M---^ ^^^ ";,S^.^^;; ' . . : ’ � ^ H ^ ^ ^ ^ ^ J ^ ^ ^ _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
^^ i^ ^^ y^mjijQpj^ ^^ ^^ ^m 
— m ^ ^ B i 
H ^ ^ ^ ^ ^ H H ^ l B ^ R ^ i ^ t e ^ g l | ^l^ | # |^:lfl| g M
� Chapter 4 
^^ ^^ ^^ ^^ ^^ ^^ H^ 
{ • • 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ | 
^ ^ ^ 9 H | 
- — ~ ~ ~ ~ " ~ " ― ^ ~ 厂 . 一 .:•--. :'• -:*•:-.…v〗一-.___v丨…'-^ :^― 
,J[Sf<A “ • • • 
# 4k 
f W ^ ^ 
4 3 P ^ ’ > j ^ � : ^ S� 茨1 l I 
T%" ^^-
^ L ^ ^ ^ L • • • .^^  
\� 徵� ^ ^ ^ ^ ^ ^ 霧�, : : : A ^ 
- - ' ^ M ^ ^ V . ^ ‘ : ^ L :�;::i::vJ 
•、.�..� • T . - ~ • . . : , - -• -.乂�.�.,:•/,.-.-..-�--•-:..，�
V - . - -:.- . * _. • ，，“-.. - • - . � ..-_-、-., ；^ --•； . .:. J 
;-• _. . “-- - . - ~ .、：“.，-二二.厂.• - ...... .，• ._ . ,. 1 • -. - • • ••.'  - -, •- ‘ :::.•::" ••.:,:-_- 二.-“ .. 
;:“_.二-:.”：义.-.：• .;。、- ->： ;„!，-:-- -^T::k^4^>S^^.^-rg:-:v-. ^ - .-： ^^:-:^¾^..,.,/,- 二 .：-.:、.:-、.、力：：_^1^-二'丄",.:：-"•'- -0.'^y:>^r.- :;>?:-::.�. 
Figure 5.3 Taxaracum mongolicum Hand. Mazz. 
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Figure 5.4 Cinnabaris 
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Figure 5.5a Mean plasma ciprofloxacin concentration with ( • ) 
and without ( • ) Sanguisorba officinalis L. (200mgyTkg) 
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Figure 5.5b Mean plasma ciprofloxacin concentration with ( • ) 
and without ( • ) Foeniculum vulgare Mill, (200mg/l^) 
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Figure 5.5c Mean plasma ciprofloxacin concentration with ( • ) 
and without (# ) Taxaracum mongolicum Hand, Mazz, 
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Figure 5.5d Mean plasma ciprofloxacin concentration with ( • ) 
and w i t h o u t ( . ; Cinnabaris (200mgyTkg) 











































































































































































































































































































































































































































































































































































































































































Ciprofloxacin possesses a broad spectrum of antimicrobial activity and is 
proven to be efficacious in the treatment of serious infectious against Pseudomonas 
aeruginsa and Staphylococcus aureus. (Walker R.C. et al, 1987). Both oral and 
parenteral form ofciprofloxacin are available. One of the advantages of ciprofloxacin 
use is the potential to provide a cost-effective alternative for the treatment of 
infections caused by organisms that are resistant to previously available antibiotics. 
However, a potential problem with the use of ciprofloxacin is its ability to form 
chelates and thus inactivation by metal cations. The 4-oxo-3-carboxylic acid group of 
the molecular which is believed to be responsible for antimicrobial activity of 
V 
ciprofloxacin is also the possible chelation site for various cations. Although metal-
chelate formation is a known problem for ciprofloxacin, there are several reasons for 
coadministration of cation-containing agents; one prominent reason is a 5-10% 
incidence of gastric upsets resulting from quinolone administration (Neu H.C., 1987 
and Nix D.E. et al., 1987a). Many previous studies have demonstrated that the 
absorption of oral ciprofloxacin is impaired by 'the concomitant administration of 
magnesium and aluminum containing antacids C^ i^x D.E. et al., 1989b and Frost R.W. 
et al., 1992). Therefore, the administration of antacids 6 h before or 2 h after oral 
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ciprofloxacin dosing is recommended to minimize the impact of these cations on the 
absorption of ciprofloxacin. However, interpretation of these previous studies are 
confined to the interactions occurring solely in the gastrointestinal tract. How the 
decrease in antimicrobial activity as a result of metal chelate formation can be 
extrapolated to the in vivo situation is not known; in particular, the effect on the 
pharmacokinetics/ pharmacodynamics of the antibiotic when both agents are present 
I 
together in the systemic circulation are poorly understood. 
Iron supplements are one of the most commonly prescribed dmgs and are also 
available as over-the-counter preparations. Therefore, interactions between ferrous 
sulfate and ciprofloxacin are clinically possible. In fact, previous reports have shown 
a large reduction in peak ciprofloxacin concentration (Cax) and area under curve 
(AUC) when ciprofloxacin was ingested with ferrous sulfate (Polk R.E. et al., 1989; 
Kara M. et al., 1991 and Lehto P, et af., 1994). The decreased bioavailability is 
presumed to be a result of the formation of a poorly absorbable iron-ciprofIoxacin 
complex in the gastrointestinal tract. However, the interaction between these two 
agents has not been well investigated especially the effect of the dosing times when 
they are administered separately. Moreover, ferrous sulfate can be absorbed from the 
gastrointestinal tract into the blood circulation, the occurrence of an interaction 
between ciprofloxacin and ferrous sulfate outside the gastrointestinal tract can be 
expected. 
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A number of studies in this thesis were designed to investigate the interaction 
of ciprofloxacin with iron in the systemic circulation in an attempt to define the 
effects of oral ferrous sulfate on the pharmacokinetics and pharmacodynamics of 
intravenous (i.v.) and oral ciprofloxacin. To achieve these objectives, ciprofloxacin 
and ferrous sulfate were administered by two different routes (i.v. ciprofloxacin and 
oral ferrous sulfate) in the first study to ensure physical interaction would not occur 
between the two species in the gastrointestinal tract. In addition, interactions between 
these two agents and their effects on the pharmacokinetic/ pharmacodynamic system 
in the systemic circulation were intensively studies using both HPLC and 
microbiological assays. Data obtained using the HPLC assay, suggest that oral 
ferrous sulfate administration caused 51% and 47% decrease in total body clearance 
(C7x) and renal clearance ((¾), respectively, of i.v. ciprofloxacin in rats. 
Furthermore, the terminal half-life (t,/2A2), AUC and volume distribution (Ka2) were 
significantly increased. However, when estimates of A UC and urinary recovery were 
assessed from data obtained by the microbiological assay (M.A.), a large degree of 
reduction in these two parameters was observed. Part of the reason for this was an 
apparent decrease in plasma ciprofloxacin concentrations 2 h after of drug 
administration when assessed by the microbiological assay as compared with that of 
the HPLC assay. It has been shown that ferrous sulfate absorbed from the 
gastrointestinal tract would yield a peak concentration in plasma at about 2 h after 
administration ofthis salt in rats (Geisser P. and Muller A., 1987). At the time of this 
peak plasma concentration of ferrous sulfate, chelation of ciprofloxacin with ferrous 
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sulfate would have potentially occurred in the systemic circulation resulting in a shift 
in the pharmacokinetic parameters of ciprofloxacin. Since metal chelate formation has 
been shown to reduce antimicrobial activity of ciprofloxacin, concentrations of the 
antibiotic generated by M.A. were apparently lower when compared to that of the 
HPLC assay. On the other hand, the reduction in Ch and Ch suggest that the formed 
iron-ciprofloxacin complex is more difficult to be eliminated. The larger Vd,xi is 
consistent with more lipophilicity when the chelates are formed and they may stay 
longer in the body. In a second study, administration of oral ferrous sulfate was 
appropriately spaced from oral dosing of ciprofloxacin i.e., ferrous sulfate given 75 
min after oral ciprofloxacin (Group D), to minimize the effect on the bioavailability of 
ciprofloxacin by avoiding physiological contact between these two agents. Although 
the pharmacokinetic parameters obtained using the HPLC assay showed no statistical 
differences，the prolongation of t1/2,x2 indicates that the interaction might have 
occurred in the circulation even when ferrous sulfate was orally dosed 75 min 
V 
following ciprofloxacin. 
The first investigation has provided strong evidence that the iron-
ciprofloxacin chelate seems to be more lipophilic such that it could stay longer in the 
body. Furthermore, the lower concentrations of ciprofloxacin obtained by the M.A. 
as compared to that of the HPLC assay strongly'suggest that the iron-ciprofloxacin 
chelate, when formed in the circulation, would cause a lower degree of antibacterial 
秦 
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effect. More importantly, ciprofloxacin concentrations quantitated by the HPLC 
assay do not necessary yield on equivalent degree of antibacterial activity. 
A part of the same .study was designed to have ferrous sulfate administered 2 
h before oral ciprofloxacin dosing (Group E) to allow maximum concentrations of 
both ferrous sulfate and ciprofloxacin for the interaction to occur in the circulation 
such that the maximum effect of interaction could be investigated. However, the 
residual amount of ferrous sulfate in the gastrointestinal tract was sufficient enough 
to reduce the absorption of ciprofloxacin. Therefore, when compared with controls, 
the AUCo-�Cniax and urinary recovery of ciprofloxacin, under this study condition 
were significantly lowed as quantitated using by the HPLC assay. As a result, ferrous 
sulfate orally dosed two hours before ciprofloxacin still can impair ciprofloxacin 
absorption and a 2 h time gap may be insufficient. 
� ’ 
V 
From the results of the above studies，the interactions between ciprofloxacin 
and ferrous sulfate are complicated processes. The demonstration of such interaction 
in the circulation is of particular clinical importance. Chelation of ciprofloxacin not 
only alters the antibiotic pharmacokinetics but also reduces its pharmacological 
activity. Therefore, it may be misleading if the concentration of ciprofloxacin is only 
quantitated by HPLC assay, and these concentrations cannot be considered as 
equivalent to antibacterial activity. The clinical implication of our findings is that 
ciprofloxacin should not, ifat all possible, be taRen with ferrous sulfate or other iron 
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salts even though an adequate time has been spaced between the two agents. This is 
especially true in treating systemic infections caused by organisms that show 
relatively high minimum inhibitory concentrations such as Pseydomonas aeruginosa 
and Staphylococcus aureus. 
Numerous investigations have confirmed the impairment of ciprofloxacin 
absorption by coadministration of various cation containing agents. The present 
investigation is the first to evaluate the effects of Traditional Chinese Medicines 
(TCM) having a high mineral content on the bioavailability of ciprofloxacin. The 
results showed that the absorption of ciprofloxacin was decreased by the 
coadministration ofthese TCMs in the decreasing order ofScmgid^iorba officinalis L. 
(SO) > Foeniciilvm vidgare Mill. (FV) > Taraxacum mongolicwn Hand. Mazz. 
(TM). However, no significant effect was demonstrated by Cinnabaris. As with other 
cation containing agents, the impairment of ciprofloxacin absorption is believed to be 
V 
the result o f the formation o f a nonabsorable cation chelate complex. Similarly to the 
effect observed between ferrous sulfate and ciprofloxacin in earlier studies, the Xm,x2 
was also prolonged by coadministration with these TCMs. It was apparent that 
portion of the minerals from the TCMs were absorbed into the bloodstream to form a 
more lipophilic cation-ciprofloxacin complex and thereby prolonging the elimination 
half-life of ciprofloxacin. Interestingly, there was no significant impact of Cinnabaris 
on the absorption of ciprofloxacin. The reason for this might be the low solubility of 
« 
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Cinnabaris to liberate a free cation for chelation with ciprofloxacin in the 
gastrointestinal tract. 
The oral absorption of ciprofloxacin was greatly impaired by coadministering 
with SO and FV. Therefore, coadministration of SO or FV to patients on 
ciprofloxacin therapy should be avoided. Since SO and TM demonstrate a number of 
pharmacological activities including antibacterial activity, the possibility of 
coadministration with ciprofloxacin may be higher than with other TCMs included in 
the present study. Based on the results collected, we recommend that patients treated 
with ciprofloxacin should avoid TCM containing minerals or if their use is absolutely 
necessary, the dosing interval between them should be as long as possible. 
The studies conducted in this thesis have investigated the impact of iron and 
other mineral containing TCMs on the absorption and in vivo activity of 
V 
ciprofloxacin. The most significant finding here is that the interaction between cations 
and ciprofloxacin is not only confined to the gastrointestinal tract but also occurs in 
the systemic circulation. More importantly, the in vivo activity of ciprofloxacin can be 
reduced when the interaction takes place in the circulation. Further studies should be 
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